Boston Scientific shares fall after cybersecurity incident disrupts operationsAugust 26, 2026 6:27 AM
IH Market News Boston Scientific (NYSE:BSX) disclosed on Tuesday that a cybersecurity incident has affected some of its information technology systems, disrupting parts of the medical device company’s operations. Shares of Boston Scientific fell 4% in premarket trading on Wednesday following the disclosure. Order processing and shipments affected The company said the incident has restricted or disrupted access to certain information systems and business applications used in its operations. Among the affected functions are Boston Scientific’s ability to process customer orders and ship products. The company expects the operational disruption and limitations on system access to continue for the time being. Boston Scientific has launched an investigation into the incident and is working with third-party cybersecurity specialists to assess the situation and contain the threat. Full impact of cyber incident remains unclear The investigation remains underway, and Boston Scientific has yet to establish a timetable for the complete restoration of the affected systems. The company also said it has not yet determined the full scope of the cybersecurity incident or whether the disruption could ultimately have a material impact on its business. With key operational systems still affected, investors are likely to monitor the duration of the disruption and any further information regarding customer orders, product shipments and the potential financial consequences. Boston Scientific stock priceThe post Boston Scientific shares fall after cybersecurity incident disrupts operations appeared first on US Editors. Original: Boston Scientific shares fall after cybersecurity incident disrupts operations

Penumbra, Inc. Reports Second Quarter 2026 Financial ResultsJuly 30, 2026 4:05 PM
PR Newswire (US) ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025.Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025.Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025.Gross profit margin of 67.9% in the second quarter of 2026, an increase of 1.9% compared to the second quarter of 2025.Total operating expenses of $223.9 million in the second quarter of 2026, comprised of R&D of $25.4 million and SG&A of $198.5 million, which includes $6.9 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.Income from operations of $41.0 million and net income of $34.8 million in the second quarter of 2026.Full Year 2026 Financial Outlook and Webcast and Conference Call Information
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026.About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X. Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.Penumbra, Inc.Condensed Consolidated Balance Sheets(unaudited)(in thousands)


June 30, 2026
December 31, 2025Assets



Current assets:



     Cash and cash equivalents
$           205,271
$           186,897     Marketable investments
453,524
357,919     Accounts receivable, net
190,407
190,021     Inventories
442,650
431,549     Prepaid expenses and other current assets
52,270
50,298          Total current assets
1,344,122
1,216,684Property and equipment, net
146,718
117,436Operating lease right-of-use assets
167,194
173,587Finance lease right-of-use assets
24,357
25,972Intangible assets, net
5,742
6,186Goodwill
166,523
166,750Deferred taxes
79,376
79,188Other non-current assets
40,691
40,716         Total assets
$         1,974,723
$         1,826,519Liabilities and Stockholders' Equity



Current liabilities:



     Accounts payable
$             44,728
$             34,736     Accrued liabilities
172,270
132,163  Current operating lease liabilities
14,398
13,841  Current finance lease liabilities
2,380
2,393          Total current liabilities
233,776
183,133Non-current operating lease liabilities
176,304
182,751Non-current finance lease liabilities
19,628
20,714Other non-current liabilities
14,249
12,318          Total liabilities
443,957
398,916Stockholders' equity:



Common stock
39
39Additional paid-in capital
1,224,278
1,185,525Accumulated other comprehensive income
1,363
4,348Retained earnings
305,086
237,691Total stockholders' equity
1,530,766
1,427,603Total liabilities and stockholders' equity
$         1,974,723
$         1,826,519 Penumbra, Inc.Condensed Consolidated Statements of Operations(unaudited)(in thousands, except share and per share amounts)


Three Months Ended June 30,
Six Months Ended June 30,

2026
2025
2026
2025Revenue
$       390,046
$       339,455
$       764,804
$       663,595Cost of revenue
125,102
115,445
246,449
223,702Gross profit
264,944
224,010
518,355
439,893Operating expenses:







Research and development
25,396
23,218
47,778
45,295Sales, general and administrative
198,509
159,964
391,304
313,420Total operating expenses
223,905
183,182
439,082
358,715Income from operations
41,039
40,828
79,273
81,178Interest and other income, net
5,148
4,482
8,602
7,990Income before income taxes
46,187
45,310
87,875
89,168Provision for income taxes
11,376
40
20,480
4,675Net income
$         34,811
$         45,270
$         67,395
$         84,493








Net income per share:







Basic
$            0.88
$            1.17
$            1.71
$            2.18Diluted
$            0.88
$            1.15
$            1.70
$            2.15Weighted average shares outstanding:







Basic
39,353,965
38,834,917
39,314,912
38,699,307Diluted
39,572,059
39,245,953
39,572,347
39,214,027 Penumbra, Inc.Reconciliation of Revenue Growth by Geographic Regions(unaudited)(in thousands, except for percentages)


Three Months Ended June 30,
Change

2026
2025
$
%United States
$      305,445
$      260,818
$      44,627
17.1 %International
84,601
78,637
5,964
7.6 %Total
$      390,046
$      339,455
$      50,591
14.9 %


Six Months Ended June 30,
Change

2026
2025
$
%United States
$      601,832
$      517,678
$      84,154
16.3 %International
162,972
145,917
17,055
11.7 %Total
$      764,804
$      663,595
$    101,209
15.3 % Penumbra, Inc.Reconciliation of Revenue Growth by Product Categories(unaudited)(in thousands, except for percentages)


Three Months Ended June 30,
Change

2026
2025
$
%Thrombectomy
$      258,981
$      230,256
$      28,725
12.5 %Embolization and Access
131,065
109,199
21,866
20.0 %Total
$      390,046
$      339,455
$      50,591
14.9 %


Six Months Ended June 30,
Change

2026
2025
$
%Thrombectomy
$      512,898
$      456,800
$      56,098
12.3 %Embolization and Access
251,906
206,795
45,111
21.8 %Total
$      764,804
$      663,595
$    101,209
15.3 %Investor Relations
Penumbra, Inc.
investors@penumbrainc.com View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-second-quarter-2026-financial-results-302838410.htmlSOURCE Penumbra, Inc. Original: Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts SharesJuly 29, 2026 8:27 AM
IH Market News Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The company reported earnings of $0.86 per share for the quarter, ahead of analysts’ consensus estimate of $0.83. Revenue increased to $5.44 billion, representing 7% operational and organic growth and surpassing market expectations of $5.37 billion. Broad-Based Growth Across Business Segments Boston Scientific delivered growth across both of its core operating divisions during the quarter. The MedSurg segment recorded reported net sales growth of 5.9%, with operational and organic growth of 5.4%. Meanwhile, the Cardiovascular business continued to outperform, posting reported net sales growth of 8.3%, while operational and organic growth reached 7.8%. International Markets Support Revenue Growth The company also reported strong performance across its major geographic regions. In the United States, net sales increased 6.2% on both a reported and operational basis. The Europe, Middle East and Africa (EMEA) region recorded reported growth of 6.1%, with operational growth of 4.2%. Asia-Pacific (APAC) delivered the strongest performance among the major regions, with both reported and operational sales increasing 11.2%. Revenue in Latin America and Canada climbed 22.4% on a reported basis and 16.2% on an operational basis. CEO Highlights Long-Term Growth Strategy Chairman and Chief Executive Officer Mike Mahoney said: “Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific’s long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.” Updated Guidance Falls Short of Market Expectations Despite the stronger-than-expected second-quarter performance, Boston Scientific issued earnings guidance that came in below analysts’ forecasts. For the full year, the company expects earnings per share of between $3.28 and $3.32, compared with the consensus estimate of $3.36. Boston Scientific continues to forecast organic net sales growth of approximately 5% to 6% for the year. For the third quarter, the company expects adjusted earnings per share of between $0.80 and $0.82, below analysts’ expectations of $0.84. The company also forecast reported and organic net sales growth of approximately 3% to 5% during the quarter. Boston Scientific stock priceThe post Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares appeared first on US Editors. Original: Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares

Boston Scientific announces results for second quarter 2026July 29, 2026 6:30 AM
PR Newswire (US) MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago. "Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."Second quarter financial results and recent developments: Reported net sales of $5.442 billion, representing an increase of 7.5 percent on a reported basis, compared to the company's guidance range of 5.5 to 7.5 percent; and 7.0 percent on an operational and organic basis, compared to the company's guidance range of 5 to 7 percent, all compared to the prior year period.Reported GAAP net income attributable to Boston Scientific common stockholders of $0.61 per share, and achieved adjusted EPS of $0.86 per share, compared to the guidance range of $0.82 to $0.84 per share.Achieved the following net sales growth in each reportable segment, compared to the prior year period:MedSurg: 5.9 percent reported, 5.4 percent operational and organicCardiovascular: 8.3 percent reported, 7.8 percent operational and organicAchieved the following net sales growth in each region, compared to the prior year period:United States (U.S.): 6.2 percent reported and operationalEurope, Middle East and Africa (EMEA): 6.1 percent reported and 4.2 percent operationalAsia-Pacific (APAC): 11.2 percent reported and operationalLatin America and Canada (LACA): 22.4 percent reported and 16.2 percent operationalCompleted the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.Invested $1.5 billion in MiRus LLC, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.4Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.4Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including:The AVANT GUARD study of FARAPULSE™ Pulsed Field Ablation (PFA) for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.The ELEVATE-PF feasibility study of the FARAFLEX™ Mapping and PFA Catheter — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.4 Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.4 Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter, expanding Boston Scientific's embolization portfolio with a device designed to provide physicians with a single solution for navigation and efficient embolic delivery during minimally invasive procedures.1.Operational net sales growth excludes the impact of foreign currency fluctuations.2.Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.3.Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.4.The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.Net sales for the second quarter by business and region:




Increase/(Decrease)

          Three Months Ended                    June 30,          
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational Basis
Impact of
Certain
Acquisitions
/Divestitures
Organic
Basis(in millions)20262025





   Endoscopy$      793$      737
7.6 %
(0.7) %
7.0 %
— %
7.0 %
   Urology684676
1.1 %
(0.3) %
0.8 %
— %
0.8 %
   Neuromodulation                                      341303
12.7 %
(0.6) %
12.2 %
— %
12.2 %
MedSurg1,8181,716
5.9 %
(0.5) %
5.4 %
— %
5.4 %
Cardiovascular3,6243,345
8.3 %
(0.6) %
7.8 %
— %
7.8 %Net Sales$    5,442$    5,061
7.5 %
(0.5) %
7.0 %
— %
7.0 %






















Increase/(Decrease)




          Three Months Ended                    June 30,          
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational Basis
(in millions)
2026
2025



U.S.
$     3,426
$     3,224
6.2 %
— %
6.2 %
EMEA
932
878
6.1 %
(1.9) %
4.2 %
APAC
878
790
11.2 %
(0.0) %
11.2 %
LACA
206
169
22.4 %
(6.2) %
16.2 %
Net Sales
$    5,442
$    5,061
7.5 %
(0.5) %
7.0 %


Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.


Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not           
prepared in accordance with U.S. GAAP.Guidance for Full Year and Third Quarter 2026The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.Conference Call InformationBoston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.Use of Non-GAAP Financial InformationA reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.CONTACT:



?          Media:Chanel Hastings
Investors:Lauren Tengler

508-382-0288 (office)

508-683-4479 (office)

Media Relations

Investor Relations

Boston Scientific Corporation

Boston Scientific Corporation

chanel.hastings@bsci.com

BSXInvestorRelations@bsci.com BOSTON SCIENTIFIC CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)

          Three Months Ended                    June 30,          ?          Six Months Ended                    June 30,          (in millions, except per share data)20262025
20262025





Net sales$      5,442$      5,061
$     10,646$      9,724Cost of products sold (excluding amortization expense)1,5941,637
3,1843,090Gross profit3,8483,424
7,4626,633





Operating expenses:




Selling, general and administrative expenses1,8031,716
3,5833,312Research and development expenses554526
1,069969Royalty expense1214
2428Amortization expense233225
466444Intangible asset impairment charges—46
—46Contingent consideration net expense (benefit)(16)(5)
(46)0Restructuring net charges (credits)883
1193Litigation-related net charges (credits)76—
76—
2,6702,605
5,1834,894Operating income (loss)1,178819
2,2791,740





Other income (expense):




Interest expense(96)(90)
(186)(172)Other, net(23)213
129179Income (loss) before income taxes1,060941
2,2221,746Income tax expense (benefit)155146
(21)279Net income (loss)905795
2,2431,467Net income (loss) attributable to noncontrolling interests(2)(2)
(4)(4)Net income (loss) attributable to Boston Scientific common stockholders                                        $        907$        797
$      2,247$      1,471





Net income (loss) per common share - basic$        0.62$        0.54
$        1.52$        0.99Net income (loss) per common share - diluted$        0.61$        0.53
$        1.51$        0.98





Weighted-average shares outstanding




Basic1,470.21,479.9
1,477.61,478.5Diluted1,474.81,493.5
1,484.91,493.3





Amounts may not add due to rounding.




 BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS(Unaudited)

Three Months Ended June 30, 2026(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$   3,848$   2,670$   1,178$    (118)$   1,060$     905$           (2)$          907$   0.61Non-GAAP adjustments:








Amortization expense—(233)233—23320622030.14Acquisition/divestiture-related net
charges/credits30(61)9119272—720.05Restructuring and restructuring-related net
charges/credits25(16)42—4237—370.02Litigation-related net charges/credits—(76)76—7660—600.04Investment portfolio net losses/gains and
impairments———(2)(2)(2)—(2)(0.00)EU MDR implementation costs4(3)7—76—60.00IEEPA tariff refund(83)—(83)—(83)(77)—(77)(0.05)Deferred tax expenses/benefits—————70—700.05Adjusted$   3,824$   2,281$   1,543$    (120)$   1,423$   1,275$            1$        1,275$   0.86




















Three Months Ended June 30, 2025(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$   3,424$   2,605$     819$     122$     941$     795$           (2)$          797$   0.53Non-GAAP adjustments:








Amortization expense—(225)225—22519321910.13Goodwill and other intangible asset impairment
charges —(46)46—4637—370.02Acquisition/divestiture-related net
charges/credits46(92)138(230)(92)(92)—(92)(0.06)Restructuring and restructuring-related net
charges/credits37(124)161—161142—1420.10Investment portfolio net losses/gains and
impairments———(2)(2)(2)—(2)(0.00)EU MDR implementation costs7(3)10—109—90.01Deferred tax expenses/benefits—————45—450.03Discrete tax items—————0—00.00Adjusted$   3,514$   2,114$   1,399$    (110)$   1,289$   1,127$            0$        1,127$   0.75









An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.Amounts may not add due to rounding.


BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS(Unaudited)

Six Months Ended June 30, 2026(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$   7,462$   5,183$   2,279$     (57)$   2,222$   2,243$           (4)$        2,247$   1.51Non-GAAP adjustments:








Amortization expense—(466)466—46641054060.27Acquisition/divestiture-related net
charges/credits57(118)175(36)139103—1030.07Restructuring and restructuring-related net
charges/credits47(29)77—7769—690.05Litigation-related net charges/credits—(76)76—7660—600.04Investment portfolio net losses/gains and
impairments———(139)(139)(106)—(106)(0.07)EU MDR implementation costs9(5)14—1412—120.01IEEPA tariff refund(83)—(83)—(83)(77)—(77)(0.05)Deferred tax expenses/benefits—————(250)—(250)(0.17)Adjusted$   7,492$   4,490$   3,002$    (232)$   2,771$   2,465$            1$        2,464$   1.66




















Six Months Ended June 30, 2025(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$   6,633$   4,894$   1,740$       6$   1,746$   1,467$           (4)$        1,471$   0.98Non-GAAP adjustments:








Amortization expense—(444)444—44438343780.25Goodwill and other intangible asset impairment
charges —(46)46—4637—370.02Acquisition/divestiture-related net
charges/credits136(150)286(229)5761—610.04Restructuring and restructuring-related net charges/credits61(149)210—210184—1840.12Investment portfolio net losses/gains and
impairments———665—50.00EU MDR implementation costs15(7)23—2319—190.01Deferred tax expenses/benefits—————91—910.06Discrete tax items—————0—00.00Adjusted$   6,846$   4,097$   2,749$    (216)$   2,533$   2,249$            1$        2,248$   1.51









An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATIONQ3 and FY 2026 GUIDANCE RECONCILIATIONS(Unaudited)





Net Sales

?


                    Q3 2026 Estimate                    
               Full Year 2026 Estimate               
(Low)(High)
(Low)(High)Reported growth3.0 %5.0 %
5.5 %6.5 %Impact of foreign currency fluctuations— %— %
(0.5) %(0.5) %Operational growth3.0 %5.0 %
5.0 %6.0 %Impact of certain acquisitions/divestitures                                                              — %— %
— %— %Organic growth3.0 %5.0 %
5.0 %6.0 %Use of Non-GAAP Financial MeasuresTo supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, we may incur certain charges such as severance and other compensation-related charges, fixed asset write-offs, contract cancellations, facility shutdown costs, and inventory write-downs associated with discontinuations of significant product lines. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.Deferred tax expenses (benefits) - These amounts represent significant non-cash tax benefits arising from internal reorganizations or intra-entity asset transfers. The deferred tax effects related to the establishment and subsequent reversal of net deferred tax assets are excluded from management's assessment of operating performance used for making operating decisions and assessing performance.IEEPA tariff refund - This amount relates to the benefit recognized in connection with the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA) recognized in Cost of products sold within our unaudited consolidated statements of operations. This amount is excluded from management's assessment of operating performance used for making operating decisions and assessing performance.The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance. View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-second-quarter-2026-302837127.htmlSOURCE Boston Scientific Corporation Original: Boston Scientific announces results for second quarter 2026

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpointsMay 19, 2026 6:31 AM
PR Newswire (US) Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well as procedural success. Findings from the trial were presented in a late-breaking trial session at the EuroPCR 2026 congress. Moderate-to-severe coronary calcification – a hardened build-up of calcium that can narrow coronary arteries – is present in nearly one-third of patients undergoing percutaneous coronary intervention (PCI) to treat CAD, presenting a major challenge that can complicate stent delivery and expansion and increase the risk of procedural complications such as vessel dissection.1 The SEISMIQ 4CE catheter is an intravascular lithotripsy (IVL) device that uses laser energy within a balloon catheter to generate acoustic pressure waves that fracture calcium. The system's visible, directional emitters are designed to provide controlled, consistent energy delivery at low pressure to treat the calcium and prepare the vessel for stent implantation and maximum stent expansion to restore blood flow."As the prevalence of coronary artery disease and adoption of IVL therapy to address it continue to grow rapidly, data from this important trial will help advance our understanding of treatment for severely diseased, previously untreated coronary lesions and could help broaden the scope of coronary IVL treatment options over time," said Dr. Margaret McEntegart, M.D., PhD, co-principal investigator of the FRACTURE trial and director of Complex PCI and CTO Programs at Columbia University Irving Medical Center, New York.** "Notably, stents were successfully delivered in all patients treated, no deaths occurred and only one patient underwent target vessel revascularization at the 30-day follow up, underscoring reassuring safety data for the SEISMIQ 4CE device."  The prospective, non-randomized, single-arm FRACTURE trial enrolled 420 patients with severe CAD. Findings from the trial met all pre-specified safety and effectiveness endpoints. Of note:The primary safety endpoint was met with a 93.3% rate of freedom from MACE, including cardiovascular death, myocardial infarction or target vessel revascularization at 30 days, exceeding a prespecified performance goal of 86.2% (p < 0.0001).A 93.7% rate of procedural success met the primary effectiveness endpoint, defined as successful stent delivery with a final residual stenosis of less than 50% and freedom from in-hospital MACE, exceeding a prespecified performance goal of 85.8% (p 0.0001).Treatment with the SEISMIQ 4CE device resulted in 100% successful stent delivery and final in-stent residual stenosis less than 50%.A sub-analysis of the data found a 94.2% average stent expansion rate at the most calcified segment of the artery, with favorable stent sizing that exceeded clinically significant thresholds, helping to create space within the vessel and support optimal stent placement.2"Representing one of the fastest growing medical device segments in both peripheral and coronary care, IVL therapy can help address a critical level of coronary artery narrowing or blockage that poses a threat of heart attack, heart failure and other serious complications," said Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, Boston Scientific. "The data presented today serves as pivotal evidence to support our regulatory submission for the SEISMIQ 4CE catheter, which may provide physicians a new, differentiated coronary IVL device option to address severe calcium during the lesion prep phase of complex PCI procedures, potentially improving outcomes for these high-risk patients."The trial enrolled patients who will be followed for two years after their procedure across 46 sites in the United States and Europe. The investigational SEISMIQ 4CE Coronary IVL Catheter is compatible with the same console used in the SEISMIQ™ IVL System with the SEISMIQ™ IVL Peripheral Catheter, which received U.S. Food and Drug Administration (FDA) clearance in 2025 for the treatment of patients with severely calcified peripheral artery disease.For more information on the FRACTURE trial, visit bostonscientific.com/fracture.About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.  Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, product approvals and launches, product performance and impact, and clinical trials. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACTS:
Angela Mineo
Media Relations
+1 (412) 491-9713
Angela.mineo @TraderXx 
BSXInvestorRelations@bsci.com*Caution: Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale.
**Dr. Margaret McEntegart is a paid consultant of Boston Scientific Corporation. She has not been compensated in connection with this press release.1 Barbato E, Gallinoro E, Abdel-Wahab M, et al. Management strategies for heavily calcified coronary stenoses: an EAPCI clinical consensus statement in collaboration with the EURO4C-PCR group. Eur Heart J. Nov 1 2023;44(41):4340-4356. doi:10.1093/eurheartj/ehad342
2 Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, Meneveau N, de la Torre Hernandez JM, Escaned J, Hill J, Prati F, Colombo A, di Mario C, Regar E, Capodanno D, Wijns W, Byrne RA, Guagliumi G; ESC Scientific Document Group. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018 Sep 14;39(35):3281-3300. doi: 10.1093/eurheartj/ehy285. Erratum in: Eur Heart J. 2019 Jan 14;40(3):308. doi: 10.1093/eurheartj/ehy460. PMID: 29790954 View original content to download multimedia:https://www.prnewswire.com/news-releases/fracture-ide-trial-of-the-boston-scientific-seismiq-4ce-coronary-intravascular-lithotripsy-catheter-meets-primary-safety-and-effectiveness-endpoints-302776040.htmlSOURCE Boston Scientific Corporation Original: FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Boston Scientific Shares Rise After $2 Billion Buyback and MiRus Investment (BSX)May 18, 2026 10:30 AM
IH Market News Stock Gains Following Capital Allocation Announcements Shares of Boston Scientific (NYSE:BSX) rose 2.1% in premarket trading on Monday after the company announced a $2 billion accelerated share repurchase program alongside a $1.5 billion strategic investment in MiRus LLC. Accelerated Buyback Program Underway Boston Scientific entered into an accelerated share repurchase agreement with JPMorgan Chase covering $2 billion of its common stock as part of the company’s previously authorized $5 billion share repurchase plan.Under the agreement, the company expects to initially receive approximately 30.4 million shares based on the May 15 closing price of $52.68, representing 80% of the total repurchase amount.Final settlement of the transaction is anticipated by June 30, 2026.Following completion of the program, Boston Scientific will still have approximately $3 billion available under its existing buyback authorization.The company said the accelerated repurchase is expected to increase adjusted earnings per share by approximately $0.02 during full-year 2026, adding to guidance previously issued on April 22, 2026. Company Invests $1.5 Billion in MiRus Separately, Boston Scientific announced a $1.5 billion investment in privately held MiRus LLC in exchange for an approximately 34% equity stake.MiRus is developing cardiovascular and orthopedic technologies, including the investigational SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement system.The agreement also grants Boston Scientific an exclusive option to acquire MiRus’ TAVR business, subject to milestone achievements and additional payments. SIEGEL Valve Features Novel Materials and Design According to the company, the SIEGEL TAVR valve uses a proprietary rhenium alloy and is described as the first nickel-free balloon-expandable TAVR valve.The device incorporates dry porcine tissue leaflets along with a nitric oxide-coated rhenium frame.Boston Scientific said all valve sizes can be delivered using an 8 French expandable sheath, which is approximately 50% smaller than delivery systems currently available commercially. Future Acquisition Could Cost Additional $3 Billion Boston Scientific may choose to acquire the MiRus TAVR business by making additional cash payments totaling up to $3 billion after certain clinical and regulatory milestones are achieved.The company said the MiRus investment is expected to have an immaterial impact on adjusted earnings per share during 2026.The SIEGEL TAVR system remains investigational and has not yet received approval for commercial sale.Boston Scientific stock price Original: Boston Scientific Shares Rise After $2 Billion Buyback and MiRus Investment (BSX)

Boston Scientific enters into $2 billion accelerated share repurchase agreementMay 18, 2026 7:00 AM
PR Newswire (US) MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, Boston Scientific will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52.68. The total number of shares that Boston Scientific will ultimately repurchase under the ASR will be determined based on the volume-weighted average price of the company's common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed by June 30, 2026. Following completion of the ASR, Boston Scientific will have $3 billion remaining available under the share repurchase authorization. The expected net impact to adjusted earnings per share from the accelerated share repurchase in full year 2026 is $0.02, accretive to Boston Scientific's previously issued guidance on April 22, 2026.About Boston Scientific 
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the benefits of the ASR and the expected impact to adjusted earnings per share, the number of shares to be repurchased under the ASR and the timing and manner of the final settlement under the ASR agreement, business plans and strategy, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.Factors that may cause such differences include, among other things:  economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; market competition for our products; expected procedural volumes; new product introductions; demographic trends; the closing and integration of acquisitions; clinical trial results; intellectual property; litigation; financial market conditions; future business decisions made by us and our competitors; and the execution and effect of our business strategy, including our cost-savings and growth initiatives. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.CONTACTS: 
Chanel Hastings 
Media Relations
+1 (508) 382-0288
Chanel.Hastings @TraderXx
BSXInvestorRelations@bsci.com View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-enters-into-2-billion-accelerated-share-repurchase-agreement-302774240.htmlSOURCE Boston Scientific Corporation Original: Boston Scientific enters into $2 billion accelerated share repurchase agreement

Boston Scientific announces strategic investment in MiRus LLCMay 18, 2026 6:30 AM
PR Newswire (US) Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloyMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has invested $1.5 billion in return for an approximately 34% equity stake in MiRus LLC, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. As part of the investment agreement, Boston Scientific also received an exclusive option to acquire the MiRus TAVR system, subject to additional payments and the completion of certain milestones. The SIEGEL technology is built on a proprietary rhenium alloy and is the first nickel-free, balloon-expandable TAVR valve intended to restore function and normal blood flow of severely narrowed aortic valves."The occurrence and recognition of aortic stenosis is growing rapidly and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio that we anticipate may improve outcomes for patients living with this life-threatening disease," said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies, Boston Scientific. "Built upon years of research and proprietary technology, we believe the distinctive design and impressive early clinical results of the SIEGEL valve may set it apart from currently available technology, potentially providing physicians an advanced option to treat a wide array of patients."The SIEGEL TAVR valve is designed with leaflets made of dry porcine tissue and a nitric oxide-coated rhenium frame, which has a radial strength greater than cobalt or titanium.1 The open cell design of the frame is intended to eliminate foreshortening and aide precise placement in the heart. Uniquely, the valve is also pre-mounted directly onto the balloon and all sizes – 23 mm, 26 mm and 29 mm – can be precisely delivered through an 8 French expandable sheath, which is approximately 50% smaller2 than current commercially available TAVR delivery sheaths and may minimize vascular injuries.MiRus recently initiated the STAR pivotal trial that is evaluating the safety and effectiveness of the three sizes of the SIEGEL valve in up to 1,025 patients with severe, symptomatic aortic stenosis considered to be at low, intermediate or high risk for surgical complications. Last year, MiRus presented findings from an early feasibility study assessing the safety and performance of the device."The SIEGEL valve is a promising technology and has received enthusiastic feedback from physician investigators for its less invasive delivery, nickel-free construct, precise placement resulting from a lack of foreshortening and excellent hemodynamics," said Jay Yadav, M.D., founder and chief executive officer, MiRus. "This collaborative relationship with Boston Scientific alongside the exceptional capabilities of our Atlanta-based team can further accelerate our progress towards broad accessibility for patients and physicians for what we believe will be a transformational treatment."The investment in MiRus is expected to be immaterial to adjusted earnings per share for Boston Scientific in 2026. Boston Scientific may exercise the option to acquire the MiRus TAVR business by making additional aggregate cash payments totaling $3 billion, at Boston Scientific's option following MiRus' achievement of certain clinical and regulatory milestones, that would result in 100% ownership of the TAVR business, subject to customary closing conditions. If Boston Scientific exercises the option, MiRus will have the right to receive additional payments based on net sales of the SIEGEL TAVR valve over a specified period and Boston Scientific will also have an exclusive option to acquire mitral and tricuspid replacement valve assets from MiRus for an additional payment. Caution: The SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system is an investigational device, which is not yet approved for commercial distribution in any country.1 Per ASTM standards specification
2 Edwards eSheath+ Introducer Set Instructions for Use (2023-08 10058349001 A)About Boston Scientific 
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the financial and business impact of the investment and the anticipated benefits of the investment, the exercise of the option and the timing thereof, business plans and strategy, clinical trials, product approvals and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.Factors that may cause such differences include, among other things:  economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; market competition for our products; expected procedural volumes; new product introductions; demographic trends; the closing and integration of acquisitions, including our ability or determination to exercise the option and our ability to achieve the anticipated benefits of the investment or the option (if exercised); clinical trial results; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the investment or the exercise of the option; intellectual property; litigation; financial market conditions; future business decisions made by us and our competitors; the execution and effect of our business strategy, including our cost-savings and growth initiatives; the conditions to the completion of the investment or the exercise of the option, including the receipt of any required regulatory approvals and clearances, may not be satisfied at all or in a timely manner; and the fact that the exercise of the option may not occur or may be delayed. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.CONTACTS: 
Laura Aumann 
Media Relations 
(651) 582-4251
laura.aumann @TraderXx
BSXInvestorRelations@bsci.com View original content:https://www.prnewswire.com/news-releases/boston-scientific-announces-strategic-investment-in-mirus-llc-302774205.htmlSOURCE Boston Scientific Corporation Original: Boston Scientific announces strategic investment in MiRus LLC

Penumbra, Inc. Reports First Quarter 2026 Financial ResultsMay 6, 2026 4:05 PM
PR Newswire (US) ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025.Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026.Full Year 2026 Financial Outlook and Webcast and Conference Call Information
Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026.About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.Penumbra, Inc.Condensed Consolidated Balance Sheets(unaudited)(in thousands)


March 31, 2026
December 31, 2025Assets



Current assets:



     Cash and cash equivalents
$            241,289
$            186,897     Marketable investments
374,371
357,919     Accounts receivable, net
183,295
190,021     Inventories
438,539
431,549     Prepaid expenses and other current assets
37,912
50,298          Total current assets
1,275,406
1,216,684Property and equipment, net
134,059
117,436Operating lease right-of-use assets
170,273
173,587Finance lease right-of-use assets
25,209
25,972Intangible assets, net
5,946
6,186Goodwill
166,589
166,750Deferred taxes
79,972
79,188Other non-current assets
40,984
40,716         Total assets
$         1,898,438
$         1,826,519Liabilities and Stockholders' Equity



Current liabilities:



     Accounts payable
$             43,658
$             34,736     Accrued liabilities
151,543
132,163  Current operating lease liabilities
14,144
13,841  Current finance lease liabilities
2,386
2,393          Total current liabilities
211,731
183,133Non-current operating lease liabilities
179,424
182,751Non-current finance lease liabilities
20,221
20,714Other non-current liabilities
13,250
12,318          Total liabilities
424,626
398,916Stockholders' equity:



Common stock
39
39Additional paid-in capital
1,201,423
1,185,525Accumulated other comprehensive income
2,075
4,348Retained earnings
270,275
237,691Total stockholders' equity
1,473,812
1,427,603Total liabilities and stockholders' equity
$         1,898,438
$         1,826,519




 Penumbra, Inc.Condensed Consolidated Statements of Operations(unaudited)(in thousands, except share and per share amounts)


Three Months Ended March 31,

2026
2025Revenue
$            374,758
$            324,140Cost of revenue
121,347
108,257Gross profit
253,411
215,883Operating expenses:



Research and development
22,382
22,077Sales, general and administrative
192,795
153,456Total operating expenses
215,177
175,533Income from operations
38,234
40,350Interest and other income, net
3,454
3,508Income before income taxes
41,688
43,858Provision for income taxes
9,104
4,635Net income
$             32,584
$             39,223




Net income per share:



Basic
$                0.83
$                1.02Diluted
$                0.82
$                1.00Weighted average shares outstanding:



Basic
39,275,424
38,562,191Diluted
39,543,780
39,163,428 Penumbra, Inc.Reconciliation of Revenue Growth by Geographic Regions(unaudited)(in thousands, except for percentages)


Three Months Ended March 31,
Change

2026
2025
$
%United States
$      296,387
$      256,860
$      39,527
15.4 %International
78,371
67,280
11,091
16.5 %Total
$      374,758
$      324,140
$      50,618
15.6 % Penumbra, Inc.Reconciliation of Revenue Growth by Product Categories(unaudited)(in thousands, except for percentages)


Three Months Ended March 31,
Change

2026
2025
$
%Thrombectomy
$      253,917
$      226,544
$      27,373
12.1 %Embolization and Access
120,841
97,596
23,245
23.8 %Total
$      374,758
$      324,140
$      50,618
15.6 %Investor Relations
Penumbra, Inc.
investors@penumbrainc.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-first-quarter-2026-financial-results-302764359.htmlSOURCE Penumbra, Inc. Original: Penumbra, Inc. Reports First Quarter 2026 Financial Results

Data at Heart Rhythm 2026 highlight key Boston Scientific therapiesApril 26, 2026 1:00 PM
PR Newswire (US)

Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions MARLBOROUGH, Mass. and CHICAGO, April 26, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's FARAPULSE™ Pulsed Field Ablation (PFA) Platform and WATCHMAN™ Left Atrial Appendage Closure (LAAC) technologies. All data were presented at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society, held in Chicago from April 24-26.







Results from the AVANT GUARD clinical trial of FARAPULSE™ PFA
The randomized AVANT GUARD clinical trial met all safety and effectiveness endpoints and demonstrated statistical superiority of PFA over anti-arrhythmic drugs (AADs) with significantly higher primary effectiveness. The trial is the first randomized pivotal study to evaluate patients with persistent atrial fibrillation (AF) who had not previously been treated for their condition – a historically understudied, high-risk population. Patients were randomized or assigned to receive pulmonary vein isolation (PVI) and left atrial posterior wall isolation (PWI) using the FARAWAVE™ PFA Catheter or given AADs for treatment. Results were simultaneously published in The New England Journal of Medicine.Key findings from the trial:PFA achieved superiority over AADs with a primary effectiveness rate of 56.0% at 12 months compared to 30.1% in the AAD group.The primary safety endpoint was met with major adverse event rate of 5.1% at 12 months.Significantly more patients in the PFA group (51.7%) were free from atrial arrhythmia recurrence at 12 months, compared to 32.2% in the AAD group.Results from the feasibility study of the FARAFLEX™ PFA Catheter
The single-arm, ELEVATE-PF feasibility trial is examining the safety and effectiveness of the FARAFLEX PFA Catheter, a novel, high-density large focal map-and-ablate catheter designed to treat complex arrhythmias, in patients with paroxysmal and persistent AF. The trial enables ongoing PFA dosing and workflow refinements based on a study design incorporating prospective high-density remapping, analyzing patients sequentially in three groups – feasibility, improved and optimized.Key findings from this ongoing trial:With workflow improvements, PVI durability – the permanence of an ablation lesion over time – increased from 80.4% on a per-vein basis in the feasibility group (n=13) to 96.4% in the optimized group (n=34).Within the optimized group, PVI durability in patients with persistent AF was 95.6% at two months (n=17).There were no reports of stroke, pulmonary vein stenosis, hemolysis or coronary spasm.Clinical outcomes associated with real-world concomitant PFA and LAAC interventions
Prospective, interim, real-world evidence from ALIGN-AF, a multi-center sub-study of the DISRUPT-AF registry, reinforced that concomitant procedures combining the FARAWAVE PFA Catheter and the WATCHMAN FLX™ Pro LAAC Device could be performed safely without compromising acute procedural success. The study, which includes 122 patients at 12 sites with 24 physicians performing the procedures, assessed peri-device leaks between 45 and 90 days following implant and will assess arrhythmia recurrence at six and 12 months.Key findings from available data at three months:Ablation with the FARAWAVE PFA Catheter achieved a 100% (n=122/122) acute success rate. Ablation parameters such as lesion sets and procedure duration were consistent with those observed in standalone PFA procedures.LAAC with the WATCHMAN FLX Pro implant also achieved 100% (n=119/119) procedural success and 90.6% (n=96/106) complete LAA closure at a mean of 66 days with no clinically relevant leaks or device-related thrombus reported.Sub-analysis of the CHAMPION-AF clinical trial in patients with or without prior ablation
A sub-analysis of the CHAMPION-AF trial studied LAAC therapy with the WATCHMAN FLX implant compared to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with and without prior ablation for non-valvular atrial fibrillation (NVAF). The analysis included 1,434 patients who had a cardiac ablation for AF prior to randomization and 1,565 patients who did not have a previous ablation. The results highlighted that for patients in both arms of the sub-analysis, the device provided statistically significant protection from non-procedural bleeding and had similar efficacy to NOACs.Key findings from the sub-analysis:The WATCHMAN FLX device provided statistically significant protection from non-procedural bleeding, including major and clinically relevant non-major bleeding (CRNMB), compared to NOACs in patients who had a prior ablation (9.0% vs. 17.0%) and in patients with no prior ablation (12.8% vs. 20.8%).CRNMB is defined within the trial as life-impacting non-major bleeds that require medical intervention, hospitalization or an increased level of care.The WATCHMAN FLX device had similar efficacy to NOACs for the occurrence of stroke, cardiovascular or unexplained death, or systemic embolism, regardless of whether they had a prior ablation (3.9% for both the device and NOACs in patients with prior ablation; 7.5% for the device group vs. 5.7% for the NOAC group in patients with no prior ablation).Long-term outcomes after LAAC therapy in patients not eligible for anticoagulation
Five-year follow-up data from the ASAP-TOO trial provided evidence on the legacy WATCHMAN LAAC device (n=284) or the WATCHMAN FLX LAAC device (n=20) compared to a single antiplatelet (SAPT) medication or no medication in reducing the risk of ischemic stroke or systemic embolism in patients with NVAF who were deemed unsuitable for oral anticoagulation (OAC) medication. While the findings contribute new clinical data on LAAC and stroke protection, interpretation is limited as the trial ended early due to slow enrollment driven by physician preference for the device over SAPT/no medication, not safety-related factors, and variability in long-term follow-up.Key findings from the trial:There was a lower rate of occurrence of stroke or systemic embolism with an LAAC device compared to the control group (7.8% vs. 11.4%).LAAC therapy was associated with significantly fewer disabling strokes compared to the control group (1.1% vs. 3.8%).The device group had a rate of 1.0% for all-cause death, ischemic stroke, systemic embolism or device- or procedure-related events requiring open cardiac surgery or major endovascular intervention within discharge or seven days.Results from the investigator-sponsored PRAETORIAN DFT study of the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) were also presented as a late-breaking clinical trial, meeting the primary endpoint. Findings from the trial achieved non-inferiority in the likelihood of failed therapy when omitting defibrillation testing as guided by the PRAETORIAN score – an estimate of successful delivery of life-saving therapy – in patients receiving the device for the first time.1"The data presented at Heart Rhythm 2026 reflect the continued momentum of our cardiovascular portfolio and underscores our commitment to advancing innovation through comprehensive clinical evidence across the spectrum of cardiac care," said Kenneth Stein, M.D., senior vice president and global chief medical officer, Boston Scientific. "These findings support the potential expansion of our FARAPULSE PFA Platform into more complex patient populations, highlight the value of a combined therapeutic approach with our WATCHMAN FLX Pro LAAC Device, may enhance the implant experience with the EMBLEM MRI S-ICD and position us to deliver a broader portfolio of differentiated solutions for physicians treating patients with cardiovascular diseases."About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.  Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact, and clinical trials. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things:  economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACTS:
Steve Bailey
Media Relations
+1 (651) 582-4343 (office)
Steve.Bailey @TraderXx
BSXInvestorRelations@bsci.com











1 The manufacturer recommended VF conversion testing during EMBLEM S-ICD implant, replacement, and concomitant device implants is being evaluated based on the PRAETORIAN DFT trial results and additional available data.



View original content to download multimedia:https://www.prnewswire.com/news-releases/data-at-heart-rhythm-2026-highlight-key-boston-scientific-therapies-302753735.htmlSOURCE Boston Scientific Corporation

Original: Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Boston Scientific announces results for first quarter 2026April 22, 2026 6:30 AM
PR Newswire (US)

MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion or $0.90 per share (EPS), compared to $674 million or $0.45 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.75 a year ago.







"Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems."First quarter financial results and recent developments: Reported net sales of $5.203 billion, representing an increase of 11.6 percent on a reported basis, compared to the company's guidance range of 10.5 to 12.0 percent; and 9.4 percent on an operational and organic basis, compared to the company's guidance range of 8.5 to 10.0 percent, all compared to the prior year period.Reported GAAP net income attributable to Boston Scientific common stockholders of $0.90 per share, and achieved adjusted EPS of $0.80 per share, compared to the guidance range of $0.78 to $0.80 per share.Achieved the following net sales growth in each reportable segment, compared to the prior year period:MedSurg: 7.8 percent reported, 5.7 percent operational and organicCardiovascular: 13.5 percent reported, 11.2 percent operational and organicAchieved the following net sales growth in each region, compared to the prior year period:United States (U.S.): 10.9 percent reported and operationalEurope, Middle East and Africa (EMEA): 10.1 percent reported and 1.2 percent operationalAsia-Pacific (APAC): 14.7 percent reported and 12.0 percent operationalLatin America and Canada (LACA): 19.0 percent reported and 12.0 percent operationalAnnounced clinical trial results that were presented in late-breaking sessions at the 75th Annual Scientific Session of the American College of Cardiology and simultaneously published in The New England Journal of Medicine including: The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction, which met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation (AF). The HI-PEITHO clinical trial evaluating the EKOS™ Endovascular System for the treatment of acute pulmonary embolism (PE) in patients with intermediate-risk PE, which demonstrated the EKOS system plus anticoagulation was superior to anticoagulation alone.Announced positive outcomes from the ADVENT Long-Term Outcomes clinical trial, which demonstrated greater long-term AF treatment success, fewer hospital-based arrhythmia interventions and lower repeat ablation rates at four years with FARAPULSE™ Pulsed Field Ablation (PFA) compared to thermal ablation.Received National Medical Products Association approval in China for the OPAL HDx™ Mapping System, which enables catheter visualization during FARAPULSE PFA procedures. Published in Chronic Pain and Management Journal outcomes from the 24-month COMFORT clinical trial demonstrating durable and statistically significant pain relief and improved quality of life with peripheral nerve stimulation therapy with the Nalu Neurostimulation System compared to conventional medical management in patients with chronic pain.Received U.S. Food and Drug Administration 510(k) clearance for the Asurys™ Fluid Management System, designed to provide real-time irrigation management during endoscopic urologic procedures; when used with the LithoVue™ Elite Single-Use Flexible Ureteroscope System, it also supports intrarenal pressure (IRP) management during ureteroscopy.Completed the acquisition of?Valencia Technologies Corporation, a privately held company focused on the development and commercialization of the eCoin® System, an implantable tibial nerve stimulation device for the treatment of urge urinary incontinence.Elected to the company's board of directors Cathy Smith, chief financial officer of Starbucks, and Christophe Weber, president and chief executive officer of Takeda Pharmaceutical.1. Operational net sales growth excludes the impact of foreign currency fluctuations.2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and discrete tax items.Net sales for the first quarter by business and region:




Increase/(Decrease)

Three Months Ended
March 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational Basis
Impact of
Certain
Acquisitions
/Divestitures
Organic
Basis(in millions)20262025





   Endoscopy$       736$       673
9.4 %
(2.6) %
6.8 %
— %
6.8 %
   Urology646633
2.1 %
(1.6) %
0.5 %
— %
0.5 %
   Neuromodulation                                               318271
17.4 %
(1.9) %
15.4 %
— %
15.4 %
MedSurg1,7011,577
7.8 %
(2.1) %
5.7 %
— %
5.7 %
Cardiovascular3,5033,085
13.5 %
(2.3) %
11.2 %
— %
11.2 %Net Sales$     5,203$     4,663
11.6 %
(2.2) %
9.4 %
— %
9.4 %






















Increase/(Decrease)




Three Months EndedMarch 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational Basis
(in millions)
2026
2025



U.S.
$     3,284
$     2,960
10.9 %
— %
10.9 %
EMEA
932
846
10.1 %
(8.8) %
1.2 %
APAC
803
701
14.7 %
(2.7) %
12.0 %
LACA
185
155
19.0 %
(7.0) %
12.0 %
Net Sales
$     5,203
$     4,663
11.6 %
(2.2) %
9.4 %













? Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP.Guidance for Full Year and Second Quarter 2026The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.34 to $3.41.The company estimates net sales growth for the second quarter of 2026, versus the prior year period, to be approximately 5.5 to 7.5 percent on a reported basis and 5.0 to 7.0 percent on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.82 to $0.84.The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.Conference Call InformationBoston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the second quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.Use of Non-GAAP Financial InformationA reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.CONTACT:



?          Media:Chanel Hastings
Investors:Lauren Tengler

508-382-0288 (office)

508-683-4479 (office)

Media Relations

Investor Relations

Boston Scientific Corporation

Boston Scientific Corporation

chanel.hastings@bsci.com

BSXInvestorRelations@bsci.com BOSTON SCIENTIFIC CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)

Three Months EndedMarch 31,(in millions, except per share data)20262025


Net sales$      5,203$      4,663Cost of products sold (excluding amortization expense)1,5901,453Gross profit3,6143,210


Operating expenses:

Selling, general and administrative expenses1,7811,597Research and development expenses516443Royalty expense1214Amortization expense232219Contingent consideration net expense (benefit)(30)5Restructuring net charges (credits)310
2,5132,288Operating income (loss)1,101921


Other income (expense):

Interest expense(90)(82)Other, net151(34)Income (loss) before income taxes1,162805Income tax expense (benefit)(176)133Net income (loss)1,339672Net income (loss) attributable to noncontrolling interests(2)(2)Net income (loss) attributable to Boston Scientific common stockholders                                                                                            $      1,341$         674


Net income (loss) per common share - basic$        0.90$        0.46Net income (loss) per common share - diluted$        0.90$        0.45


Weighted-average shares outstanding

Basic1,484.91,477.2Diluted1,495.01,493.1


Amounts may not add due to rounding.

 BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS(Unaudited)

Three Months Ended March 31, 2026(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$    3,614$    2,513$    1,101$      61$    1,162$    1,339$            (2)$         1,341$   0.90Non-GAAP adjustments:








Amortization expense—(232)232—23220522020.14Acquisition/divestiture-related net
charges/credits27(56)83(36)4732—320.02Restructuring and restructuring-related net
charges/credits22(13)35—3533—330.02Investment portfolio net losses/gains and
impairments———(137)(137)(104)—(104)(0.07)EU MDR implementation costs5(2)7—76—60.00Deferred tax expenses/benefits—————(320)—(320)(0.21)Adjusted$    3,668$    2,209$    1,459$    (112)$    1,347$    1,190$             0$         1,189$   0.80




















Three Months Ended March 31, 2025(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$    3,210$    2,288$     921$    (116)$     805$     672$            (2)$          674$   0.45Non-GAAP adjustments:








Amortization expense—(219)219—21918921870.13Acquisition/divestiture-related net
charges/credits89(58)1481149154—1540.10Restructuring and restructuring-related net
charges/credits24(24)49—4942—420.03Investment portfolio net losses/gains and
impairments———887—70.00EU MDR implementation costs9(4)12—1211—110.01Deferred tax expenses/benefits—————47—470.03Adjusted$    3,332$    1,982$    1,350$    (106)$    1,243$    1,121$             0$         1,121$   0.75









An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATIONQ2 and FY 2026 GUIDANCE RECONCILIATIONS(Unaudited)
Net Sales





           Q2 2026 Estimate          
     Full Year 2026 Estimate      
(Low)(High)
(Low)(High)Reported growth5.5 %7.5 %
7.0 %8.5 %Impact of foreign currency fluctuations(0.5) %(0.5) %
(0.5) %(0.5) %Operational growth5.0 %7.0 %
6.5 %8.0 %Impact of certain acquisitions/divestitures                                                                                   — %— %
— %— %Organic growth5.0 %7.0 %
6.5 %8.0 %





Use of Non-GAAP Financial MeasuresTo supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, we may incur certain charges such as severance and other compensation-related charges, fixed asset write-offs, contract cancellations, facility shutdown costs, and inventory write-downs associated with discontinuations of significant product lines. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.Deferred tax expenses (benefits) - These amounts represent significant non-cash tax benefits arising from internal reorganizations or intra-entity asset transfers. The deferred tax effects related to the establishment and subsequent reversal of net deferred tax assets are excluded from management's assessment of operating performance used for making operating decisions and assessing performance.The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.



View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-first-quarter-2026-302749437.htmlSOURCE Boston Scientific Corporation

Original: Boston Scientific announces results for first quarter 2026

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpointsMarch 28, 2026 10:55 AM
PR Newswire (US)

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF). Key results were presented as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in The New England Journal of Medicine.







Atrial fibrillation (AF) is an increasingly common heart rhythm disorder that affects approximately 59 million people worldwide1 and increases stroke risk by five times compared to people with a normal heart rhythm.2 In patients with NVAF, more than 90% of heart-related blood clots form in the left atrial appendage (LAA).3 An alternative to long-term NOACs – considered the leading contemporary blood thinners for stroke risk reduction in patients with NVAF – the WATCHMAN technology is designed to permanently close off the LAA and is implanted in a single procedure."The success of the landmark CHAMPION-AF trial represents a meaningful milestone that will undoubtedly transform the treatment approach to stroke risk reduction in a broader population of patients who historically have needed to rely on medication," said Martin Leon, M.D., study co-chair and Mallah Family professor of cardiology, chief innovation officer and director, Cardiovascular Data Science Center, Columbia University Medical Center.* "These results should give clinicians confidence in the potential of the WATCHMAN FLX device to become a first-line treatment option for reducing the risk of stroke for a rapidly growing number of patients with AF."The randomized, controlled trial enrolled 3,000 patients with NVAF who were suitable for oral anticoagulation therapy across a broad spectrum of stroke and bleeding risk. At 36 months:The primary safety endpoint was met with data demonstrating the WATCHMAN FLX device was statistically superior to NOACs (10.9% vs. 19.0%; P

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolismMarch 28, 2026 10:38 AM
PR Newswire (US)

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation aloneLate breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating that the EKOS system plus anticoagulation was superior to the current standard of care – anticoagulation alone – for the treatment of acute PE. Findings from the trial were presented in a late-breaking science session at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in The New England Journal of Medicine.







PE is a blood clot that causes a blockage in one or more pulmonary arteries that bring blood to the lungs, and is the third leading cause of cardiovascular mortality.1 Current medical guidelines for treating PE recommend medical management with anticoagulation as the standard of care for patients at all risk levels. A minimally invasive intervention, the EKOS system delivers a low dose of clot-dissolving medication directly to the blood clot and uses ultrasound energy to facilitate the dispersion of the medication deep into the clot to dissolve it."The data presented today offer clinicians a greater understanding of the impact of intervention via ultrasound-facilitated catheter-directed thrombolysis with the EKOS system," said Dr. Stavros Konstantinides, MD, PhD, FESC, principal investigator of the HI-PEITHO trial and medical director, Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany.* "These highly anticipated findings underscore the clinical efficacy for patients treated with this therapy, while also demonstrating that treatment was not accompanied by an increased risk of major bleeding and offered the added benefit of a shorter hospital stay compared to patients treated with anticoagulation alone."The trial met the combined primary endpoint of PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse and non-fatal symptomatic recurrence of PE within seven days. The EKOS system plus anticoagulation demonstrated superiority to anticoagulation alone (4.0% vs. 10.3%; P=0.005), representing a 61% reduction in primary endpoint events. Data from patients treated with the EKOS system also demonstrated a lower rate of cardiorespiratory decompensation or collapse (3.7% vs. 10.3%), in which inability of the heart to maintain adequate blood flow can lead to serious complications, often requiring emergency intervention. These results were achieved with no episodes of bleeding within the brain through 30 days."The HI-PEITHO trial evaluated clear, clinically meaningful endpoints using rigorous patient enrollment criteria and demonstrated a definitive impact with the EKOS system over the standard of care for treating acute PE," said Dr. Michael R. Jaff, vice president and chief medical officer, Vascular Therapies, Boston Scientific. "For the first time, we have robust randomized clinical trial data available to inform treatment decisions by interventionalists and referring physicians and support consideration of EKOS plus anticoagulation as a first-line therapy."The randomized, controlled HI-PEITHO trial enrolled 544 patients with intermediate-risk PE across 59 sites in the United States and Europe. The trial is a joint research study led by Boston Scientific in partnership with The PERT Consortium® and the University Medical Center of Mainz and in collaboration with the PEITHO International Study Network. Patients will be followed to one year post procedure.For more information on the HI-PEITHO trial, visit https://www.bostonscientific.com/hi-peitho.About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.  Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, product performance and impact, and clinical trials. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACTS:
Blake Rouhani
Media Relations
+1 (763) 494-2268
Blake.rouhani @TraderXx
BSXInvestorRelations@bsci.com* Dr. Stavros Konstantinides is a paid consultant of Boston Scientific Corporation. He has not been compensated in connection with this press release.1 Wendelboe, A.M, et al. Global Burden of Thrombosis: Epidemiologic Aspects. Circulation Research.2016 Apr 29; 118(9): 1340-1347. doi: 10.1161/CIRCRESAHA.115.306841.










View original content to download multimedia:https://www.prnewswire.com/news-releases/hi-peitho-trial-demonstrates-boston-scientific-ekos-endovascular-system-is-superior-to-standard-of-care-for-treatment-of-acute-pulmonary-embolism-302727904.htmlSOURCE Boston Scientific Corporation

Original: HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of CardiologyMarch 6, 2026 8:00 AM
PR Newswire (US)

MARLBOROUGH, Mass., March 6, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m. CT to discuss key clinical data presented earlier that day at the 75th Annual Scientific Session of the American College of Cardiology. The event will be hosted by Dr. Kenneth Stein, senior vice president and global chief medical officer, Dr. Brad Sutton, chief medical officer, AF solutions and Dr. Michael R. Jaff, vice president and chief medical officer, vascular therapies.







The live webcast and replay of the event will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings @TraderXx
BSXInvestorRelations@bsci.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-to-host-investor-event-at-the-75th-annual-scientific-session-of-the-american-college-of-cardiology-302705865.htmlSOURCE Boston Scientific Corporation

Original: Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 25, 2026 1:00 PM
PR Newswire (US)

ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.







Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter of 2025, an increase of 12.4% compared to the fourth quarter of 2024.U.S. Thrombectomy revenue of $771.5 million for the full year 2025, an increase of 19.3% compared to the full year 2024.Income from operations of $59.2 million or operating margin of 15.4% for the fourth quarter of 2025. Income from operations of $189.2 million or operating margin of 13.5% for the full year 2025.Net income of $47.3 million and adjusted EBITDA1 of $79.1 million or net income margin of 12.3% and adjusted EBITDA margin1 of 20.5% for the fourth quarter of 2025. Net income of $177.7 million and adjusted EBITDA1 of $266.8 million or net income margin of 12.7% and adjusted EBITDA margin1 of 19.0% for the full year 2025.Fourth Quarter 2025 Financial Results
Total revenue increased to $385.4 million for the fourth quarter of 2025 compared to $315.5 million for the fourth quarter of 2024, an increase of 22.1%, or 20.9% in constant currency1. The United States represented 77.6% of total revenue and international represented 22.4% of total revenue for the fourth quarter of 2025. Revenue from the U.S. increased 20.6% while revenue from our international regions increased 27.7%, or 21.9% in constant currency1. Revenue from sales of our global thrombectomy products grew to $254.7 million in the fourth quarter of 2025, an increase of 15.7%, or 14.7% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 12.4%. Revenue from sales of our global embolization and access products grew to $130.7 million in the fourth quarter of 2025, an increase of 37.0%, or 35.2% in constant currency1 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 42.7% from the same period a year ago.Gross profit for the fourth quarter of 2025 was $262.1 million, or 68.0% of total revenue compared to $210.7 million, or 66.8% of total revenue, for the fourth quarter of 2024. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.Total operating expenses were $202.9 million, or 52.6% of total revenue for the fourth quarter of 2025. This compares to total operating expenses of $167.9 million, or 53.2% of total revenue for the fourth quarter of 2024. R&D expenses were $21.8 million for the fourth quarter of 2025, compared to $20.0 million for the fourth quarter of 2024. SG&A expenses were $181.1 million for the fourth quarter of 2025, compared to $147.9 million for the fourth quarter of 2024.Income from operations was $59.2 million for the fourth quarter of 2025, compared to income from operations of $42.8 million for the fourth quarter of 2024.Full Year 2025 Financial Results
Total revenue increased to $1,403.7 million for the year ended December 31, 2025 compared to $1,194.6 million for the year ended December 31, 2024, an increase of 17.5%, or 16.9% in constant currency1. The United States represented 77.8% of total revenue and international represented 22.2% of total revenue for the year ended December 31, 2025. Revenue from the U.S. increased 21.0% while revenue from our international regions increased 6.6%, or 4.2% in constant currency1. Revenue from sales of our global thrombectomy products grew to $947.9 million for the year ended December 31, 2025, an increase of 16.2%, or 15.8% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 19.3%. Revenue from sales of our global embolization and access products grew to $455.7 million for the year ended December 31, 2025, an increase of 20.2%, or 19.4% in constant currency1 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 25.4% from the same period a year ago.Gross profit for the year ended December 31, 2025 was $942.4 million, or 67.1% of total revenue, compared to $755.0 million, or 63.2% of total revenue, for the year ended December 31, 2024, which included a one-time $33.4 million inventory impairment charge to cost of revenue in connection with the impairment of our immersive healthcare asset group. The impact of the one-time $33.4 million charge decreased our gross margin by 2.8 percentage points in 2024. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.Total operating expenses for the year ended December 31, 2025 were $753.2 million, or 53.7% of total revenue. This compares to total operating expenses of $745.7 million, or 62.4% of total revenue for the year ended December 31, 2024. R&D expenses were $89.8 million for the year ended December 31, 2025, compared to $94.8 million for the year ended December 31, 2024. SG&A expenses were $663.4 million for the year ended December 31, 2025, compared to $574.0 million for the year ended December 31, 2024.Income from operations was $189.2 million for the year ended December 31, 2025 compared to income from operations of $9.3 million for the year ended December 31, 2024.1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.Full Year 2026 Financial Outlook
Given the proposed acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026.Webcast and Conference Call Information
Given the proposed acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be hosting a conference call to discuss financial results for the fourth quarter and year ended December 31, 2025.About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X. Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency, b) non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share ("EPS") and c) adjusted EBITDA and adjusted EBITDA margin.Constant currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;the excess tax benefits associated with share-based compensation arrangements;non-recurring litigation related expenses;non-cash long-lived asset impairment related to the impairment of our immersive healthcare asset group; andone-time expenses in connection with the wind down of the immersive healthcare business.Adjusted EBITDA and adjusted EBITDA margin. The Company's adjusted EBITDA reflects the exclusion from GAAP net income of:non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges;non-operating items such as interest income, interest expense, and provision for income taxes;non-recurring litigation related expenses; andone-time expenses in connection with the wind down of the immersive healthcare business.Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees, non-cash long-lived asset impairment charges related to the impairment of our immersive healthcare asset group, and one-time expenses in connection with the wind down of the immersive healthcare business. Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as interest income, interest expense, and provision for income taxes, non-recurring litigation related expenses, and one-time expenses in connection with the wind down of the immersive healthcare business.The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025, which we expect to file with the SEC on or before March 2, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.Penumbra, Inc.Condensed Consolidated Balance Sheets(unaudited)(in thousands) 

December 31,

2025
2024Assets



Current assets:



     Cash and cash equivalents
$           186,897
$           324,404     Marketable investments
357,919
15,727     Accounts receivable, net
190,021
167,668     Inventories
431,549
406,737     Prepaid expenses and other current assets
50,298
36,589          Total current assets
1,216,684
951,125Property and equipment, net
117,436
62,641Operating lease right-of-use assets
173,587
177,787Finance lease right-of-use assets
25,972
28,018Intangible assets, net
6,186
6,513Goodwill
166,750
165,826Deferred taxes
79,188
100,332Other non-current assets
40,716
40,939          Total assets
$        1,826,519
$        1,533,181Liabilities and Stockholders' Equity



Current liabilities:



     Accounts payable
$             34,736
$             31,326     Accrued liabilities
132,163
112,429     Current operating lease liabilities
13,841
12,221     Current finance lease liabilities
2,393
2,369          Total current liabilities
183,133
158,345Non-current operating lease liabilities
182,751
187,068Non-current finance lease liabilities
20,714
21,731Other non-current liabilities
12,318
15,106          Total liabilities
398,916
382,250Stockholders' equity:



Preferred stock
—
—Common stock
39
38Additional paid-in capital
1,185,525
1,096,732Accumulated other comprehensive income (loss)
4,348
(5,843)Retained earnings
237,691
60,004Total stockholders' equity
1,427,603
1,150,931  Total liabilities and stockholders' equity
$        1,826,519
$        1,533,181 Penumbra, Inc.Condensed Consolidated Statements of Operations(unaudited)(in thousands, except share and per share amounts) 

Three Months Ended December 31,
Year Ended December 31,

2025
2024
2025
2024Revenue
$           385,385
$           315,518
$        1,403,665
$        1,194,615Cost of revenue
123,257
104,797
461,228
439,620     Gross profit
262,128
210,721
942,437
754,995Operating expenses:







     Research and development
21,794
20,010
89,766
94,783     Sales, general and administrative
181,101
147,936
663,422
573,988  Impairment Charge
—
—
—
76,945          Total operating expenses
202,895
167,946
753,188
745,716Income from operations
59,233
42,775
189,249
9,279Interest and other income, net
4,399
1,564
15,876
11,590Income before income taxes
63,632
44,339
205,125
20,869Provision for income taxes
16,289
10,656
27,438
6,857Net income
$             47,343
$             33,683
$           177,687
$             14,012








Net income per share:







Basic
$                  1.21
$                  0.88
$                  4.57
$                  0.36Diluted
$                  1.20
$                  0.86
$                  4.52
$                  0.36Weighted average shares outstanding:







Basic
39,189,828
38,418,269
38,918,493
38,633,744Diluted
39,392,613
39,037,644
39,291,828
39,268,037 Penumbra, Inc.Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and
Non-GAAP Income from Operations1(unaudited)(in thousands) 

Three Months Ended December 31,
Year Ended December 31,

2025
2024
2025
2024








GAAP operating expenses
$             202,895
$             167,946
$             753,188
$             745,716GAAP operating expenses include the effect of the following items:







Impairment charge2
—
—
—
76,945Wind down expenses3
—
—
—
4,971Non-recurring litigation related expenses
—
—
—
4,823Amortization of finite lived intangible assets acquired
—
—
—
4,759Non-GAAP operating expenses
$             202,895
$             167,946
$             753,188
$             654,218








GAAP income from operations
$               59,233
$               42,775
$             189,249
$                 9,279GAAP income from operations includes the effect of the following items:







Impairment charge2
—
—
—
76,945Wind down expenses3
—
—
—
4,971Non-recurring litigation related expenses
—
—
—
4,823Amortization of finite lived intangible assets acquired
—
—
—
4,759Non-GAAP income from operations
$               59,233
$               42,775
$             189,249
$             100,777____________1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024.3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three months ended September 30, 2024. Penumbra, Inc.Reconciliation of GAAP Net Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1(unaudited)(in thousands, except per share amounts) 

Three Months EndedDecember 31, 2025
Three Months EndedDecember 31, 2024
Year EndedDecember 31, 2025
Year EndedDecember 31, 2024

Net
income
Diluted
EPS
Net
income
Diluted
EPS
Net
income
Diluted
EPS
Net
income
Diluted
EPSGAAP net income
$    47,343
$       1.20
$    33,683
$       0.86
$  177,687
$       4.52
$    14,012
$       0.36GAAP net income includes the effect of the following items:















Impairment charge2
—
—
—
—
—
—
76,945
1.96Wind down expenses3
—
—
—
—
—
—
4,971
0.13Non-recurring litigation expenses
—
—
—
—
—
—
4,823
0.12Amortization of finite lived intangible assets acquired
—
—
—
—
—
—
4,759
0.12Tax effect on the non-GAAP adjustments above4
—
—
—
—
—
—
(22,170)
(0.57)Excess tax benefits related to stock compensation awards
(830)
(0.02)
(343)
(0.01)
(26,804)
(0.68)
(837)
(0.02)Non-GAAP net income
$    46,513
$       1.18
$    33,340
$       0.85
$  150,883
$       3.84
$    82,503
$       2.10
















GAAP diluted EPS


$       1.20


$       0.86


$       4.52


$       0.36Non-GAAP diluted EPS


$       1.18


$       0.85


$       3.84


$       2.10____________1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024.3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three months ended September 30, 2024.4For the twelve months ended December 31, 2024, management used a combined federal and state tax rate of 24.23% to compute the tax effect of non-GAAP measures. Penumbra, Inc.Reconciliation of GAAP Net Income and GAAP Net Income Margin to Adjusted EBITDA and Adjusted EBITDA Margin1(unaudited)(in thousands, except for percentages) 

Three Months Ended December 31,
Year Ended December 31,

2025
2024
2025
2024GAAP net income
$          47,343
$          33,683
$        177,687
$          14,012Adjustments to GAAP net income







Depreciation and amortization expense
4,461
4,388
17,471
23,702Interest income, net
(4,227)
(2,939)
(14,983)
(12,272)Provision for income taxes
16,289
10,656
27,438
6,857Stock-based compensation expense
15,262
12,095
59,213
46,164Impairment charge2
—
—
—
76,945Wind down expenses3
—
—
—
4,971Non-recurring litigation related expenses
—
—
—
4,823Adjusted EBITDA
$          79,128
$          57,883
$        266,826
$        165,202








GAAP revenue
$        385,385
$        315,518
$     1,403,665
$     1,194,615Adjusted EBITDA
$          79,128
$          57,883
$        266,826
$        165,202GAAP net income margin
12.3 %
10.7 %
12.7 %
1.2 %Adjusted EBITDA margin
20.5 %
18.3 %
19.0 %
13.8 %____________1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. 2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024.3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three months ended September 30, 2024. Penumbra, Inc.Reconciliation of Revenue Change by Geographic Regions to Constant Currency Revenue Growth1(unaudited)(in thousands, except for percentages) 

Three Months Ended December 31,
Reported Change
FX Impact
Constant Currency Change

2025
2024
$
%
$
$
%United States
$       299,054
$       247,917
$         51,137
20.6 %
$                —
$         51,137
20.6 %International
86,331
67,601
18,730
27.7 %
(3,939)
14,791
21.9 %Total
$       385,385
$       315,518
$         69,867
22.1 %
$         (3,939)
$         65,928
20.9 %


Year Ended December 31,
Reported Change
FX Impact
Constant Currency Change

2025
2024
$
%
$
$
%United States   
$    1,091,761
$       902,067
$       189,694
21.0 %
$                —
$       189,694
21.0 %International
311,904
292,548
19,356
6.6 %
(7,018)
12,338
4.2 %Total
$    1,403,665
$    1,194,615
$       209,050
17.5 %
$         (7,018)
$       202,032
16.9 % Penumbra, Inc.Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1(unaudited)(in thousands, except for percentages) 

Three Months Ended December 31,
Reported Change
FX Impact
Constant Currency Change

2025
2024
$
%
$
$
%Thrombectomy
$       254,696
$       220,129
$         34,567
15.7 %
$         (2,188)
$         32,379
14.7 %Embolization and Access
130,689
95,389
35,300
37.0 %
(1,751)
33,549
35.2 %Total
$       385,385
$       315,518
$         69,867
22.1 %
$         (3,939)
$         65,928
20.9 %


Year Ended December 31,
Reported Change
FX Impact
Constant Currency Change

2025
2024
$
%
$
$
%Thrombectomy
$       947,918
$       815,475
$       132,443
16.2 %
$         (3,798)
$       128,645
15.8 %Embolization and Access
455,747
379,140
76,607
20.2 %
(3,220)
73,387
19.4 %Total
$    1,403,665
$    1,194,615
$       209,050
17.5 %
$         (7,018)
$       202,032
16.9 %


Three Months Ended December  31,
 Change
FX Impact
Constant Currency Change

2025
2024
$
%
$
$
%Thrombectomy













United States
$       203,065
$       180,647
$         22,418
12.4 %
$                —
$         22,418
12.4 %International
51,631
39,482
12,149
30.8 %
(2,188)
9,961
25.2 %Total Thrombectomy
254,696
220,129
34,567
15.7 %
(2,188)
32,379
14.7 %Embolization and Access













United States
95,989
67,270
28,719
42.7 %
—
28,719
42.7 %International
34,700
28,119
6,581
23.4 %
(1,751)
4,830
17.2 %Total Embolization and Access
130,689
95,389
35,300
37.0 %
(1,751)
33,549
35.2 %Total
$       385,385
$       315,518
$         69,867
22.1 %
$         (3,939)
$         65,928
20.9 %


Year Ended December  31,
 Change
FX Impact
Constant Currency Change

2025
2024
$
%
$
$
%Thrombectomy













United States
$       771,485
$       646,711
$       124,774
19.3 %
$                —
$       124,774
19.3 %International
176,433
168,764
7,669
4.5 %
(3,798)
3,871
2.3 %Total Thrombectomy
947,918
815,475
132,443
16.2 %
(3,798)
128,645
15.8 %Embolization and Access













United States
320,276
255,356
64,920
25.4 %
—
64,920
25.4 %International
135,471
123,784
11,687
9.4 %
(3,220)
8,467
6.8 %Total Embolization and Access
455,747
379,140
76,607
20.2 %
(3,220)
73,387
19.4 %Total
$    1,403,665
$    1,194,615
$       209,050
17.5 %
$         (7,018)
$       202,032
16.9 %____________1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com 



View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-fourth-quarter-and-full-year-2025-financial-results-302697356.htmlSOURCE Penumbra, Inc.

Original: Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Boston Scientific to participate in TD Cowen's 46th Annual Health Care ConferenceFebruary 13, 2026 8:00 AM
PR Newswire (US)

MARLBOROUGH, Mass., Feb. 13, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 30-minute question-and-answer session with the host analyst at approximately 9:10 a.m. ET.







A live webcast and replay of the session will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.  CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings @TraderXx
BSXInvestorRelations@bsci.com 



View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-to-participate-in-td-cowens-46th-annual-health-care-conference-302687094.htmlSOURCE Boston Scientific Corporation

Original: Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference

Boston Scientific Tops Q4 Forecasts, Shares Slip ModestlyFebruary 4, 2026 8:18 AM
IH Market News
Boston Scientific Corporation (NYSE:BSX) delivered stronger-than-expected results for the fourth quarter of 2025 on Wednesday, with both earnings and revenue coming in ahead of Wall Street estimates, although the stock edged lower in premarket trading.Shares of the medical device maker were down 0.47% ahead of the open following the earnings release.Adjusted earnings per share for the quarter reached $0.80, beating the consensus forecast of $0.78. Revenue totaled $5.29 billion, marginally above analysts’ expectations of $5.28 billion and up 15.9% on a reported basis from the same period a year earlier. Organic revenue growth was 12.7%, landing at the upper end of the company’s guidance range of 11% to 13%.“2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals,” said Mike Mahoney, chairman and chief executive officer. “As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future.”Growth was led by the Cardiovascular segment, which posted an 18.2% increase in reported revenue, while the MedSurg division recorded revenue growth of 11.7%. From a geographic perspective, sales in the United States rose 17.0%, and revenue from emerging markets increased 15.4%.For the full year 2025, Boston Scientific reported adjusted earnings per share of $3.06 on revenue of $20.07 billion, representing a 19.9% increase compared with 2024.Looking ahead, the company issued guidance for 2026 that calls for organic revenue growth of 10% to 11% and adjusted earnings per share in the range of $3.43 to $3.49, broadly in line with analyst expectations of $3.47.Boston Scientific also highlighted recent strategic moves, announcing agreements to acquire Penumbra, Inc. and Valencia Technologies Corporation as part of its ongoing effort to expand and strengthen its medical device portfolio.Boston Scientific stock price

Original: Boston Scientific Tops Q4 Forecasts, Shares Slip Modestly

Boston Scientific announces results for fourth quarter and full year 2025February 4, 2026 6:30 AM
PR Newswire (US)

MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.







For the full year 2025, the company generated net sales of $20.074 billion, growing 19.9 percent on a reported basis, 19.2 percent on an operational1 basis and 15.8 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $2.898 billion or $1.94 per share, compared to $1.853 billion or $1.25 per share a year ago, and delivered full year adjusted3 EPS of $3.06, compared to $2.51 a year ago."2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future."Fourth quarter financial results and recent developments:Reported net sales of $5.286 billion, representing an increase of 15.9 percent on a reported basis, compared to the company's guidance range of 14.5 to 16.5 percent; 14.3 percent on an operational basis; and 12.7 percent on an organic basis, compared to the company's guidance range of 11 to 13 percent, all compared to the prior year period.Reported GAAP net income attributable to Boston Scientific common stockholders of $0.45 per share, compared to the company's guidance range of $0.48 to $0.52 per share, and achieved adjusted EPS of $0.80 per share, compared to the guidance range of $0.77 to $0.79 per share.Achieved the following net sales growth in each reportable segment, compared to the prior year period:MedSurg: 11.7 percent reported, 10.2 percent operational and 6.5 percent organicCardiovascular: 18.2 percent reported, 16.5 percent operational and 16.1 percent organicAchieved the following net sales growth in each region, compared to the prior year period:United States (U.S.): 17.0 percent reported and operationalEurope, Middle East and Africa (EMEA): 12.4 percent reported and 4.8 percent operationalIn the second quarter of 2025, management made the decision to discontinue worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarterAsia-Pacific (APAC): 15.2 percent reported and 14.8 percent operationalLatin America and Canada (LACA): 15.9 percent reported and 10.4 percent operationalEmerging Markets4: 15.4 percent reported and 13.0 percent operationalReceived U.S. Food and Drug Administration (FDA) approval and CE mark for the FARAPOINT™ Pulsed Field Ablation (PFA) Catheter, a nav-enabled, focal PFA catheter that can create focal and linear-shaped lesions within a single device.Commenced enrollment in the OPTIMIZE clinical trial, which uses the Cortex OPTIMAP™ Electrographic Flow (EGF) Mapping Technology with the FARAPULSE™ PFA Platform?to evaluate how EGF-guided mapping and delivery of PFA to atrial fibrillation (AF) sources outside the pulmonary veins?impacts outcomes for patients with persistent AF, compared to traditional anatomic approaches.Completed enrollment in the SIMPLAAFY clinical trial evaluating two single-drug regimens as post-procedural alternatives to dual anti-platelet therapy following implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device in patients with AF.Initiated U.S. launch of the SEISMIQ™ Intravascular Lithotripsy (IVL) System to treat patients with complex calcified peripheral artery disease.Completed enrollment in the global FRACTURE IDE clinical trial evaluating the use of the SEISMIQ IVL System to treat patients with complex calcified coronary artery disease.Received U.S. FDA 510(k) clearance for the TheraSphere 360™ Y-90 Management Platform, a web-based platform that simplifies ordering TheraSphere Y-90 and helps care teams plan, dose and track the therapy for patients with liver cancer.Received positive coverage for the Intracept™ Procedure from Health Care Service Corporation and launched the Intracept EDGE J Stylet, the latest advancement to the Intracept Procedure System, designed to improve access to the basivertebral nerve and streamline the treatment experience.Commenced enrollment in the?MOSAIC study, using commercially approved Boston Scientific Spinal Cord Stimulation (SCS) Systems, to evaluate the effectiveness of time variant pulse patterns of SCS and compile real-world clinical outcomes in subjects with chronic, intractable low back and/or leg pain.Received U.S. coverage of Endoscopic Sleeve Gastroplasty (ESG), using the OverStitch™ Endoscopic Suturing System, by Elevance Health (formerly Anthem) beginning December 18, 2025, and recognition by The American Society for Metabolic and Bariatric Surgery of ESG as an endorsed procedure, expanding patient access to an innovative, less invasive weight-loss solution.Received CE mark for the MOSES Raydar™ Holmium Laser System, which is designed to increase ablation efficiency by maintaining an effective proximity range between the laser fiber tip and kidney stone during lithotripsy procedures.Announced agreement to acquire Penumbra, Inc., (NYSE: PEN) a publicly traded company that offers thrombectomy products for use in peripheral vascular procedures, minimally invasive peripheral embolization technologies and differentiated neurovascular solutions for access, stroke revascularization and neuro embolization – subject to customary closing conditions.Announced agreement to acquire Valencia Technologies Corporation, a privately held company focused on the development and commercialization of the eCoin® System, an implantable tibial nerve stimulation device for the treatment of urge urinary incontinence — subject to customary closing conditions.Completed the acquisition of?Nalu Medical, Inc., developer of the Nalu Neuromodulation System, designed to use peripheral nerve stimulation to deliver targeted relief for adults living with severe, intractable chronic pain of peripheral nerve origin.1.? Operational net sales growth excludes the impact of foreign currency fluctuations.2.
Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.3.
Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.4.
Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. Net sales for the fourth quarter by business and region:




Increase/(Decrease)

Three Months Ended
December 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational
Basis
Impact of
Certain
Acquisitions/
Divestitures
Organic
Basis(in millions)20252024





Endoscopy$          760$          690
10.1 %
(1.9) %
8.2 %
— %
8.2 %
Urology717630
13.8 %
(1.1) %
12.7 %
(9.5) %
3.2 %
Neuromodulation                                       332299
11.1 %
(1.2) %
9.9 %
— %
9.9 %
MedSurg1,8091,619
11.7 %
(1.5) %
10.2 %
(3.7) %
6.5 %
Cardiovascular3,4772,942
18.2 %
(1.7) %
16.5 %
(0.4) %
16.1 %Net Sales$       5,286$       4,561
15.9 %
(1.6) %
14.3 %
(1.6) %
12.7 %













Increase/(Decrease)




Three Months Ended
December 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational Basis(in millions)

2025
2024



U.S.


$         3,385
$         2,893
17.0 %
— %
17.0 %
EMEA


933
830
12.4 %
(7.6) %
4.8 %
APAC


788
684
15.2 %
(0.4) %
14.8 %
LACA


179
155
15.9 %
(5.5) %
10.4 %Net Sales


$         5,286
$         4,561
15.9 %
(1.6) %
14.3 %













Emerging Markets4


$           771
$           668
15.4 %
(2.5) %
13.0 %














Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.


Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP.Net sales for the full year by business and region:




Increase/(Decrease)

Year EndedDecember 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational
Basis
Impact of
Certain
Acquisitions/
Divestitures
Organic
Basis(in millions)20252024





Endoscopy$       2,916$       2,687
8.6 %
(0.8) %
7.8 %
(0.1) %
7.7 %
Urology2,7092,200
23.1 %
(0.4) %
22.7 %
(17.9) %
4.7 %
Neuromodulation                                       1,1991,106
8.4 %
(0.4) %
8.0 %
— %
8.0 %
MedSurg6,8245,993
13.9 %
(0.6) %
13.3 %
(6.6) %
6.7 %
Cardiovascular13,25010,755
23.2 %
(0.7) %
22.5 %
(1.6) %
20.8 %Net Sales$     20,074$     16,747
19.9 %
(0.7) %
19.2 %
(3.4) %
15.8 %






















Increase/(Decrease)




Year EndedDecember 31,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational Basis(in millions)

2025
2024



U.S.


$       12,864
$       10,210
26.0 %
— %
26.0 %
EMEA


3,451
3,228
6.9 %
(3.7) %
3.2 %
APAC


3,080
2,686
14.7 %
(0.2) %
14.5 %
LACA


678
624
8.7 %
2.0 %
10.7 %Net Sales


$       20,074
$       16,747
19.9 %
(0.7) %
19.2 %













Emerging Markets4


$         2,985
$         2,680
11.4 %
0.2 %
11.6 %














Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.


Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP.Guidance for Full Year and First Quarter 2026The company estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $3.43 to $3.49.The company estimates net sales growth for the first quarter of 2026, versus the prior year period, to be approximately 10.5 to 12.0 percent on a reported basis and 8.5 to 10.0 percent on an organic basis. First quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.78 to $0.80. The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.Conference Call InformationBoston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the first quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.Use of Non-GAAP Financial InformationA reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.CONTACT:             Media:Chanel Hastings?                          Investors:Lauren Tengler
508-382-0288 (office)

508-683-4479 (office)
Media Relations

Investor Relations
Boston Scientific Corporation

Boston Scientific Corporation
chanel.hastings@bsci.com

BSXInvestorRelations@bsci.com BOSTON SCIENTIFIC CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)

Three Months EndedDecember 31,
Year EndedDecember 31,in millions, except per share data20252024
20252024





Net sales$     5,286$     4,561
$    20,074$    16,747Cost of products sold (excluding amortization expense)1,6081,466
6,2215,257Gross profit3,6783,095
13,85411,490





Operating expenses:




Selling, general and administrative expenses1,8341,612
6,8875,984Research and development expenses569460
2,0521,615Royalty expense610
4633Amortization expense228225
897856Intangible asset impairment charges—111
46386Contingent consideration net expense (benefit)6(1)
18(5)Restructuring net charges (credits)164
10116Litigation-related net charges (credits)194—
194—
2,8542,420
10,2418,887Operating income (loss)825675
3,6132,603





Other income (expense):




Interest expense(90)(80)
(349)(305)Other, net(34)(10)
121(16)Income (loss) before income taxes700585
3,3852,282Income tax expense (benefit)3023
493436Net income (loss)$        670$        562
$     2,892$     1,846Net income (loss) attributable to noncontrolling interests(2)(4)
(6)(8)Net income (loss) attributable to Boston Scientific common                                                                                  
stockholders$        672$        566
$     2,898$     1,853





Net income (loss) per common share - basic$       0.45$       0.38
$       1.96$       1.26Net income (loss) per common share - diluted$       0.45$       0.38
$       1.94$       1.25





Weighted-average shares outstanding




Basic1,482.71,474.2
1,480.41,471.5Diluted1,495.81,490.2
1,494.51,485.9





Amounts may not add due to rounding.




 BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS(Unaudited)

Three Months Ended December 31, 2025(in millions, except per share data) Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income 
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$    3,678$      2,854$        825$       (124)$        700$        670$                  (2)$                672$     0.45Non-GAAP adjustments:








Amortization expense—(228)228—22819421920.13Goodwill and other intangible asset
impairment charges—————0—00.00Acquisition/divestiture-related net
charges/credits24(65)8908929—290.02Restructuring and restructuring-related net
charges/credits26(71)97—9783—830.06Litigation-related net charges/credits—(194)194—194149—1490.10Investment portfolio net losses/gains and
impairments———262626—260.02EU MDR implementation costs7(5)12—1210—100.01Deferred tax expenses/benefits—————67—670.04Discrete tax items—————(27)—(27)(0.02)Adjusted$    3,735$      2,291$      1,444$        (99)$      1,345$      1,202$                    0$              1,201$     0.80




















Three Months Ended December 31, 2024(in millions, except per share data)Gross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$    3,095$      2,420$        675$        (90)$        585$        562$                  (4)$                566$     0.38Non-GAAP adjustments:








Amortization expense—(225)225—22519821960.13Goodwill and other intangible asset
impairment charges—(111)111—11196—960.06Acquisition/divestiture-related net
charges/credits63(84)147014761—610.04Restructuring and restructuring-related net
charges/credits56(24)80—8070—700.05Litigation-related net charges/credits—————(0)—(0)(0.00)Investment portfolio net losses/gains and
impairments———221—10.00EU MDR implementation costs9(5)13—1312—120.01Deferred tax expenses/benefits—————45—450.03Discrete tax items—————(4)—(4)(0.00)Adjusted$    3,222$      1,971$      1,251$        (87)$      1,164$      1,041$                  (1)$              1,043$     0.70









An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS(Unaudited)

Year Ended December 31, 2025in millions, except per share dataGross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$  13,854$    10,241$      3,613$       (228)$      3,385$      2,892$                  (6)$              2,898$     1.94Non-GAAP adjustments:








Amortization expense—(897)897—89777097610.51Goodwill and other intangible asset
impairment charges—(46)46—4637—370.02Acquisition/divestiture-related net
charges/credits182(291)473(229)245186—1860.12Restructuring and restructuring-related net
charges/credits110(233)343—343298—2980.20Litigation-related net charges/credits—(194)194—194149—1490.10Investment portfolio net losses/gains and
impairments———262626—260.02EU MDR implementation costs29(17)46—4639—390.03Deferred tax expenses/benefits—————206—2060.14Discrete tax items—————(27)—(27)(0.02)Adjusted$  14,175$      8,563$      5,612$       (430)$      5,182$      4,577$                    3$              4,574$     3.06










Year Ended December 31, 2024in millions, except per share dataGross
ProfitOperating
ExpensesOperating
Income
(Loss)Other
Income
(Expense)Income
(Loss)
Before
Income
TaxesNet
Income
(Loss)Net Income
(Loss)
Attributable to
Noncontrolling
InterestsNet Income
(Loss)
Attributable to
Boston
Scientific
Common
StockholdersImpact
per
ShareReported$  11,490$      8,887$      2,603$       (321)$      2,282$      1,846$                  (8)$              1,853$     1.25Non-GAAP adjustments:








Amortization expense—(856)856—85674397340.49Goodwill and other intangible asset
impairment charges—(386)386—386339—3390.23Acquisition/divestiture-related net
charges/credits111(291)4021403375—3750.25Restructuring and restructuring-related net
charges/credits139(90)229—229199—1990.13Litigation-related net charges/credits—————(0)—(0)(0.00)Investment portfolio net losses/gains and
impairments———202019—190.01EU MDR implementation costs35(17)52—5245—450.03Deferred tax expenses/benefits—————165—1650.11Discrete tax items—————(4)—(4)(0.00)Adjusted$  11,776$      7,246$      4,529$       (301)$      4,229$      3,726$                    1$              3,725$     2.51









An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.Amounts may not add due to rounding. BOSTON SCIENTIFIC CORPORATIONQ1 and FY 2026 GUIDANCE RECONCILIATIONS(Unaudited)
Net Sales

   Q1 2026 Estimate   
   Full Year 2026 Estimate   
(Low)(High)
(Low)(High)Reported growth10.5 %12.0 %
10.5 %11.5 %Impact of foreign currency fluctuations(2.0) %(2.0) %
(0.5) %(0.5) %Operational growth8.5 %10.0 %
10.0 %11.0 %Impact of certain acquisitions/divestitures                                                                                                           — %— %
— %— %Organic growth8.5 %10.0 %
10.0 %11.0 %Use of Non-GAAP Financial MeasuresTo supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, in 2025, we incurred restructuring and restructuring-related net charges (credits) associated with management's decision to discontinue worldwide sales of the ACURATE neo2TM and ACURATE PrimeTM Aortic Valve Systems. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.  To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.



View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2025-302678393.htmlSOURCE Boston Scientific Corporation

Original: Boston Scientific announces results for fourth quarter and full year 2025

https://x.com/HouseLyndseyRN/status/1922683960099848396 $BSX

BSX 10Q due Oct 23

BSX anew 52 week high

Source of that info didn’t say that acquisition occurred months ago. Old news. Delete this post and previous post.

BSX acquires AXON, a neuromodulation company.

BSX new 52=high

BSX new 52+week high

BSX new 52 week high

BSX new 52 week high

BSX new 52 hi

BSX new 52 week high

BSX new 52 week high

BSX new 52 week high

BSX new 52 week high

BSX chart is very bullish. No gaps. Fundamentals looking good. Target prices rising. https://www.tipranks.com/stocks/bsx/forecast

BSX new 52 week high

Another new high today that accompanies BSX PR about its latest RCT of FARAPULSE Pulsed Field Ablation System as 1st-line treatment for persistent atrial fibrillation. FDA approval is expected in the first quarter of 2024.

BSX new 52 week high

BSX new 52 week high

BSX Chart

BSX finally looking good. Elective surgery is back.

Boston Scientific says Eluvia was 85% effective as treatment for arterial diseases

Oct. 06, 2021 1:09 PM ETBoston Scientific Corporation (BSX)

By: Dulan Lokuwithana, SA News Editor

Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) has demonstrated superiority over the self-expanding bare metal stents (BMS) in patients with a form of vascular disease, Boston Scientific (NYSE:BSX) says, citing one-year results from its EMINENT trial.

In the trial involving 775 subjects, Eluvia stent has shown ~85% of primary patency rate compared to ~76% for BMS among patients with peripheral artery disease (PAD) and superficial femoral artery (SFA)/ popliteal artery (PPA) lesions (p=0.0077).

Restricting blood flow to limbs, PAD can cause pain in affected individuals. However, a greater portion of patients who were treated with Eluvia stent experienced sustained clinical improvement without interventions (83% for Eluvia compared to ~77% for those treated with BMS at p=0.0450).

Through one year, there were no notable differences in major adverse events or all-cause mortality rates between the two patient groups, the company said.

The data were included in a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
Developed as a treatment for peripheral artery disease, Eluvia stent was granted the FDA approval in 2018.

Boston Scientific Announces Results For First Quarter 2021

Apr. 28, 2021

MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational1 basis and 5.9 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $327 million or $0.23 per share (EPS), compared to GAAP net income of $11 million or $0.01 per share a year ago, and achieved adjusted EPS of $0.37 for the period, compared to $0.28 a year ago.



"We are pleased by the trajectory of our recovery," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "Our global team remains committed to helping patients and our customers by delivering a robust portfolio of innovative solutions, and that commitment will continue to fuel our future growth."

First quarter financial results and recent developments:

Reported net sales of $2.752 billion, representing an increase of 8.2 percent on a reported basis, compared to the company's guidance range of 0 to 6 percent; 5.6 percent on an operational basis; and 5.9 percent on an organic basis, compared to the company's guidance range of (3) to 3 percent, all compared to the prior year period.

Reported GAAP net income available to common stockholders of $0.23 per share compared to the company's guidance range of $0.05 to $0.11 per share. Achieved adjusted EPS of $0.37 compared to the guidance range of $0.28 to $0.34 per share.

Achieved net sales growth in each reportable segment4, compared to the prior year period:
MedSurg: 11.1 percent reported, 8.6 percent operational and 9.5 percent organic
Rhythm and Neuro: 6.8 percent reported, 4.0 percent operational and 1.6 percent organic
Cardiovascular: 10.0 percent reported, 7.4 percent operational and organic

Achieved the following regional5 net sales growth, compared to the prior year period:
U.S.: 8.6 percent reported and operational
EMEA (Europe, Middle East and Africa): 9.4 percent reported and 1.9 percent operational
APAC (Asia-Pacific): 15.6 percent reported and 9.1 percent operational
Emerging Markets3: 16.0 percent reported and 13.2 percent operational

Received U.S. Food and Drug Administration (FDA) approval for the TheraSphere™ Y-90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer, and secured FDA Breakthrough Device designation for TheraSphere treatment for patients with glioblastoma, a type of brain cancer.6

Received approval for the Ranger™ Drug-Coated Balloon from Japan's Ministry of Health, Labor and Welfare (MHLW) and initiated a full launch in the region.

Launched Vercise Genus™ Deep Brain Stimulation (DBS) System in the U.S. Additionally, the system is being used with the world's first 16-channel directional leads—Cartesia™ X and HX leads—in the eXTend 3D Study in Europe.

Commenced U.S. launch of the WaveWriter Alpha™ portfolio of spinal cord stimulator (SCS) systems, consisting of four full-body MR conditional, Bluetooth-enabled devices, new FAST paresthesia-free therapy and all supported by Cognita™ Solutions—a suite of digital tools that helps physicians and patients navigate the pain management journey.

Surpassed 50,000 patients worldwide treated with the SENTINEL™ Cerebral Protection System, the first and only FDA-cleared device to protect patients from stroke risk during transcatheter aortic valve replacement (TAVR) procedures.

Published positive 12-month results from the PINNACLE FLX clinical trial in Circulation, demonstrating the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device is a safe and effective alternative to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation and increased risk of bleeding. The trial met its primary safety endpoint with a low adverse event rate of 0.5%, as well as its primary effectiveness endpoint with a 100% rate of LAA closure at 12 months.

Presented five-year outcomes from the EFFORTLESS study, the largest post-market registry of the Subcutaneous Implantable Defibrillator (S-ICD) System, further validating the long-term efficacy of the device. Results demonstrated 98% overall efficacy over five years, consistent with results of previous S-ICD studies and comparable to or higher than many large transvenous ICD studies.

Received FDA approval to modify the design of the ACURATE IDE trial—evaluating the ACURATE neo2™ Aortic Valve System—to an "all-risk" protocol to study patients with severe, symptomatic aortic stenosis who are at low risk of open-heart surgery, in addition to those at intermediate, high and extreme risk.

Initiated the NEwTON AF IDE clinical trial to evaluate the safety and effectiveness of the INTELLANAV STABLEPOINT™ Ablation Catheter enabled with DIRECTSENSE™ Technology in patients with paroxysmal atrial fibrillation.

Named eighth on the Forbes list of America's Best Employers for Diversity 2021, based on a survey of 50,000 Americans working for businesses with at least 1,000 employees.

Completed the acquisition of Preventice Solutions, Inc., a privately-held company which offers a full portfolio of mobile cardiac health solutions and services, for an upfront cash payment of ~$720 million, with up to an additional ~$230 million in a potential commercial milestone payment, given a preexisting 22 percent equity stake.

Completed the sale of the BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, affiliates of SERB, for ~$800 million in cash.

Announced a definitive agreement with an affiliate of Baring Private Equity Asia to acquire the global surgical business of Lumenis LTD. (LUME), a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of ~$1.07 billion, subject to customary closing conditions and adjustments.

Announced plans to host a virtual Investor Day business review meeting for the investment community on Wednesday, September 22, 2021.


1. Operational net sales growth excludes the impact of foreign currency fluctuations.

2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales from the recent acquisition of Preventice Solutions, Inc. (Preventice). Organic net sales growth rates also exclude the intrauterine health franchise, which we divested in Q2 2020 and the Specialty Pharmaceuticals business, which we divested in Q1 2021.

3. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior year amounts to conform to the current year's presentation. The revision had an immaterial impact on previously reported Emerging Markets net sales.

4. We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices).

5. On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business. Our consolidated net sales include Specialty Pharmaceuticals up to the date of the closing of the transaction. Specialty Pharmaceuticals net sales were substantially U.S. based and presented as a stand-alone operating segment alongside our Medical Device Reportable segments.

6. Consistent with Section 515B of the FD&C Act, devices designated as Breakthrough Devices will receive prioritized review (Section II.F).





Guidance for Full Year and Second Quarter 2021

The company now estimates net sales growth for the full year 2021, versus the prior year period, to be in a range of approximately 16 to 19 percent on a reported basis, and approximately 15 to 18 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and the acquisition of Preventice Solutions, Inc., with no prior period related net sales, as well as the intrauterine health franchise, which we divested in Q2 2020 and the Specialty Pharmaceuticals business, which we divested in Q1 2021. The company now estimates earnings on a GAAP basis in a range of $0.81 to $0.88 per share and estimates adjusted earnings, excluding certain charges (credits), of $1.53 to $1.60 per share.

The company estimates net sales growth for the second quarter of 2021, versus the prior year period, to be in a range of approximately 46 to 50 percent on a reported basis and approximately 44 to 48 percent on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and the acquisition of Preventice, with no prior period related net sales, as well as the intrauterine health franchise, which we divested in Q2 2020 and the Specialty Pharmaceuticals business, which we divested in Q1 2021. The company estimates earnings on a GAAP basis in a range of $0.16 to $0.18 per share and adjusted earnings, excluding certain charges (credits), of $0.36 to $0.38 per share.

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

Boston Scientific EPS beats by $0.06, beats on revenue

Apr. 28, 2021

By: Gaurav Batavia, SA News Editor

Boston Scientific (NYSE:BSX): Q1 Non-GAAP EPS of $0.37 beats by $0.06; GAAP EPS of $0.23 beats by $0.12.

Revenue of $2.75B (+8.3% Y/Y) beats by $130M.

FY21 Guidance: The company now estimates earnings on a GAAP basis in a range of $0.81 to $0.88 per share and estimates adjusted earnings, excluding certain charges (credits), of $1.53 to $1.60 per share vs. $1.54 consensus. The company now estimates net sales growth for the full year 2021, versus the prior year period, to be in a range of approximately 16 to 19 percent on a reported basis, and approximately 15 to 18 percent on an organic basis.

Q2 Guidance: The company estimates earnings on a GAAP basis in a range of $0.16 to $0.18 per share and adjusted earnings, excluding certain charges (credits), of $0.36 to $0.38 per share vs. $0.35 consensus. The company estimates net sales growth for the second quarter of 2021, versus the prior year period, to be in a range of approximately 46 to 50 percent on a reported basis and approximately 44 to 48 percent on an organic basis.
Shares +2.2% PM.

Averaging down on BSX turned out to be smart. Just took a few months as the pandemic lifts and the elective surgeries start up again.

Boston Scientific launches WaveWriter Alpha spinal cord stimulator in the U.S.

Jan. 14, 2021

Boston Scientific (BSX +0.3%) has announced a limited market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems.
It includes unified portfolio of four MRI conditional, Bluetooth-enabled rechargeable and non-rechargeable implantable pulse generators, to provide Fast Acting Sub-perception Therapy designed to deliver profound paresthesia-free pain relief in minutes.

The systems are supported by the Cognita Solutions suite of digital tools for patients and physicians.

The WaveWriter Alpha SCS Systems were approved by the FDA in December 2020 and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with failed back surgery syndrome, Complex Regional Pain Syndrome Types I and II, intractable low back pain and leg pain.

During 2020 BSX’s stock price has faced several headwinds. The medical device industry (typically seen as a secular growth and less cyclical industry) was hit hard by deferrals of more elective procedures due to the COVID-19 pandemic. Sales dropped 20 to 30% in the 2nd quarter as people around the world were locked down. Boston Scientific’s management team, out of an abundance of caution, raised equity in May leaving technical pressure on the stock.

The most recent challenge for BSX was the announcement that the company was shutting down its Lotus Edge heart valve program. The stock dropped 8.3% the day of the announcement. These challenges have resulted in sub-par performance of the stock. At the time of writing, Boston Scientific is down 22.87% YTD, while the S&P is up 17.71% and the S&P 500 Healthcare Sector is up 11.64%.

The pandemic has skewed the growth numbers and shutting down the LOTUS program has lowered the company’s growth prospects, but the story driving growth in EPS and free cash flow still remains intact. Management remains confidence that the business can grow the top-line 6 to 8% organically and expand operating margins 50 to 100bps y/y for the next couple of years (using 2019 as a base year). Based on the assumption that 2022 is a completely normalized year, it is not unreasonable for BSX to do $1.97 in EPS in 2021. A 6% to 8% topline growth rate puts BSX at the top of its peer growth in terms of growth profile which on average trade at ~23x earnings.

Applying a 23x multiple to $1.97 in EPS gets you a $45.30 stock in a year representing a 29.7% return from current trading levels. Your downside is probably around $33, down ~5%.

BSX has been a disappointment so far.

Down 25% in a matter of days.

Wow ,

A month ago we were a $40. So much
For the company doing well. Oh well
Plenty of fish in the sea.

Thanks

BSX should hold here. Looks like a Double Bottom

Were Hedge Funds Right About Piling Into Boston Scientific Corporation (BSX)?


Insider Monkey•October 20, 2020

Is Boston Scientific Corporation (NYSE:BSX) a splendid stock to buy now? Money managers were taking a bullish view. The number of bullish hedge fund bets rose by 7 in recent months. Boston Scientific Corporation (NYSE:BSX) was in 66 hedge funds' portfolios at the end of the second quarter of 2020. The all time high for this statistics is 59. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. Our calculations also showed that BSX isn't among the 30 most popular stocks among hedge funds (click for Q2 rankings and see the video for a quick look at the top 5 stocks). Video: Watch our video about the top 5 most popular hedge fund stocks.

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's monthly stock picks returned 101% since March 2017 and outperformed the S&P 500 ETFs by more than 56 percentage points. Our short strategy outperformed the S&P 500 short ETFs by 20 percentage points annually (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.


At Insider Monkey we scour multiple sources to uncover the next great investment idea. Hedge fund sentiment towards Tesla reached its all time high at the end of 2019 and Tesla shares more than quadrupled this year. We are trying to identify other EV revolution winners, so we are checking out this under-the-radar lithium stock. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website to get excerpts of these letters in your inbox. Keeping this in mind we're going to take a gander at the latest hedge fund action encompassing Boston Scientific Corporation (NYSE:BSX).


What have hedge funds been doing with Boston Scientific Corporation (NYSE:BSX)?

At Q2's end, a total of 66 of the hedge funds tracked by Insider Monkey were long this stock, a change of 12% from the first quarter of 2020. By comparison, 50 hedge funds held shares or bullish call options in BSX a year ago. With the smart money's positions undergoing their usual ebb and flow, there exists an "upper tier" of noteworthy hedge fund managers who were upping their stakes significantly (or already accumulated large positions).

The largest stake in Boston Scientific Corporation (NYSE:BSX) was held by Viking Global, which reported holding $648 million worth of stock at the end of September. It was followed by Steadfast Capital Management with a $325.1 million position. Other investors bullish on the company included OrbiMed Advisors, Marshall Wace LLP, and D E Shaw. In terms of the portfolio weights assigned to each position Parsifal Capital Management allocated the biggest weight to Boston Scientific Corporation (NYSE:BSX), around 6.56% of its 13F portfolio. Blue Whale Capital is also relatively very bullish on the stock, designating 6.07 percent of its 13F equity portfolio to BSX.

As aggregate interest increased, specific money managers were leading the bulls' herd. Bloom Tree Partners, managed by Alok Agrawal, created the most outsized position in Boston Scientific Corporation (NYSE:BSX). Bloom Tree Partners had $41.6 million invested in the company at the end of the quarter. Stephen J. Errico's Locust Wood Capital Advisers also initiated a $37.2 million position during the quarter. The following funds were also among the new BSX investors: Jeremy Green's Redmile Group, Paul Marshall and Ian Wace's Marshall Wace LLP, and Daniel S. Och's OZ Management.

Let's also examine hedge fund activity in other stocks - not necessarily in the same industry as Boston Scientific Corporation (NYSE:BSX) but similarly valued. These stocks are Intercontinental Exchange Inc (NYSE:ICE), The Bank of Nova Scotia (NYSE:BNS), Newmont Corporation (NYSE:NEM), Deere & Company (NYSE:DE), Mercadolibre Inc (NASDAQ:MELI), Kimberly Clark Corporation (NYSE:KMB), and ABB Ltd (NYSE:ABB). All of these stocks' market caps match BSX's market cap.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position ICE,60,2754652,-1 BNS,13,252173,1 NEM,55,2418239,12 DE,32,839882,-12 MELI,60,4427510,0 KMB,37,1173794,-9 ABB,10,346451,0 Average,38.1,1744672,-1.3 [/table]

View table here if you experience formatting issues.

As you can see these stocks had an average of 38.1 hedge funds with bullish positions and the average amount invested in these stocks was $1745 million. That figure was $2313 million in BSX's case. Intercontinental Exchange Inc (NYSE:ICE) is the most popular stock in this table. On the other hand ABB Ltd (NYSE:ABB) is the least popular one with only 10 bullish hedge fund positions. Compared to these stocks Boston Scientific Corporation (NYSE:BSX) is more popular among hedge funds. Our overall hedge fund sentiment score for BSX is 90. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. Our calculations showed that top 10 most popular stocks among hedge funds returned 41.4% in 2019 and outperformed the S&P 500 ETF (SPY) by 10.1 percentage points. These stocks gained 29.2% in 2020 through October 16th and still beat the market by 19.7 percentage points. Unfortunately BSX wasn't nearly as popular as these 10 stocks and hedge funds that were betting on BSX were disappointed as the stock returned 9.5% since the end of the second quarter (through 10/16) and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 10 most popular stocks among hedge funds as most of these stocks already outperformed the market in 2020.

Boston Scientific's Acurate Neo valves lacked in comparison to Medtronic’s CoreValve

Oct. 15, 2020 Vandana Singh, SA News Editor

Boston Scientific fell (BSX -4.0%), after reporting that its Scope II trial showed Acurate Neo structural heart valves failed to demonstrate non-inferiority when compared to Medtronic’s CoreValve Evolut. Results were announced during the TCT 2020 Investor Update

Total 796 patients aged 75 years or older with symptomatic severe aortic stenosis and an indication for transfemoral TAVR were recruited.

The trial missed the primary endpoint of composite of all-cause mortality or all stroke at 1 year. The primary efficacy endpoint, powered for superiority, was new permanent pacemaker implantation at 30 days. Secondary endpoints included clinical efficacy and safety endpoints at 30 days and 12 months.

In the intention-to-treat analysis, death or stroke at one year was 15.8% in the Acurate neo group compared to 13.9% in the CoreValve Evolut group, for per-protocol analysis it was 15.3% vs. 14.3%.

Noninferiority of the Acurate neo was not met for the primary endpoint in the intent-to-treat analysis, while it was met in the per-protocol analysis.

Acurate Neo2 estimated approval and U.S. launch is 2024.